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Fop-Acvr1 Signals By Multiple Modalities In The Developing Zebrafish
Abstract
Fibrodysplasia ossificans progressiva (FOP) is a rare human genetic disorder characterized by skeletal
malformations and progressive extraskeletal ossification. All cases of FOP are caused by activating
mutations in the GS or kinase domains of the type I BMP/TGFβ cell surface receptor, ACVR1, which overactivate signaling through phospho-Smad1/5 (pSmad1/5). To investigate the uncertain mechanism by
which FOP-ACVR1 enhances pSmad1/5 activation, we used a zebrafish embryonic dorsoventral (DV)
patterning assay for BMP signaling. In this system, misexpression of human ACVR1-R206H causes
increased pSmad1/5 signaling and ventralization of zebrafish embryos. To pattern the zebrafish DV axis,
Acvr1l, the zebrafish homologue of human ACVR1, signals in response to BMP ligand within a
heterotetrameric, type I and II receptor complex. Previous studies have demonstrated that type II BMP
receptors are required for the activity of FOP-ACVR1, however the roles of ligand and other type I BMP
receptors are less well understood. We determined that the FOP mutants ACVR1-R206H and -G328R do
not require their ligand binding domain to over-activate BMP signaling in DV patterning. However, intact
ACVR1-R206H and G328R have the ability to respond to BMP ligand. Additionally, BMPR1, a type I BMP
receptor which is normally required for BMP-mediated patterning of the embryo, is dispensable for both
ligand-independent and ligand-responsive BMP signaling activation by ACVR1-R206H. Both
ACVR1-R206H and -G328R require a GS domain, and presumptive type II BMP receptor activity. However,
ACVR1-R206H and -G328R have a reduced requirement for serine and threonine residues within the GS
domain compared to ACVR1. Interestingly, these FOP mutants, differ from each other in their GS domain
residue requirements for ligand-independent signaling. Over-active signaling by ACVR1-R206H and
-G328R can be abrogated by competitive ATP inhibition, confirming that kinase activity is required for
over-active signaling. Lastly, Acvr1l-R203H, the zebrafish homolog of ACVR1-R206H, does not have overactive signaling. However, the human ACVR1 kinase domain is sufficient to facilitate over-active signaling
by Acvr1l-R203H. These data provide new insight into how the ligand-receptor complex assembles and is
regulated in both wild-type and FOP BMP pathway signaling and elucidate potential targets for the
treatment of FOP.
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ABSTRACT

FOP-ACVR1 Signals by Multiple Modalities in the Developing
Zebrafish
Robyn S. Allen
Mary C. Mullins and Eileen M. Shore
Fibrodysplasia ossificans progressiva (FOP) is a rare human genetic
disorder characterized by skeletal malformations and progressive extraskeletal
ossification. All cases of FOP are caused by activating mutations in the GS or
kinase domains of the type I BMP/TGFβ cell surface receptor, ACVR1, which
over-activate signaling through phospho-Smad1/5 (pSmad1/5). To investigate
the uncertain mechanism by which FOP-ACVR1 enhances pSmad1/5 activation,
we used a zebrafish embryonic dorsoventral (DV) patterning assay for BMP
signaling. In this system, misexpression of human ACVR1-R206H causes
increased pSmad1/5 signaling and ventralization of zebrafish embryos. To
pattern the zebrafish DV axis, Acvr1l, the zebrafish homologue of human
ACVR1, signals in response to BMP ligand within a heterotetrameric, type I and II
receptor complex. Previous studies have demonstrated that type II BMP
receptors are required for the activity of FOP-ACVR1, however the roles of ligand
and other type I BMP receptors are less well understood. We determined that the
FOP mutants ACVR1-R206H and -G328R do not require their ligand binding
domain to over-activate BMP signaling in DV patterning. However, intact ACVR1R206H and G328R have the ability to respond to BMP ligand. Additionally,
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BMPR1, a type I BMP receptor which is normally required for BMP-mediated
patterning of the embryo, is dispensable for both ligand-independent and ligandresponsive BMP signaling activation by ACVR1-R206H. Both ACVR1-R206H
and -G328R require a GS domain, and presumptive type II BMP receptor activity.
However, ACVR1-R206H and -G328R have a reduced requirement for serine
and threonine residues within the GS domain compared to ACVR1. Interestingly,
these FOP mutants, differ from each other in their GS domain residue
requirements for ligand-independent signaling. Over-active signaling by ACVR1R206H and -G328R can be abrogated by competitive ATP inhibition, confirming
that kinase activity is required for over-active signaling. Lastly, Acvr1l-R203H, the
zebrafish homolog of ACVR1-R206H, does not have over-active signaling.
However, the human ACVR1 kinase domain is sufficient to facilitate over-active
signaling by Acvr1l-R203H. These data provide new insight into how the ligandreceptor complex assembles and is regulated in both wild-type and FOP BMP
pathway signaling and elucidate potential targets for the treatment of FOP.
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CHAPTER 1: Introduction
1.1: Bone Morphogenetic Protein signaling
Bone morphogenetic proteins (BMPs) are a group of transforming growth
factor Beta (TGFb) superfamily ligands named for their ability to induce
endochondral bone formation in vivo (Urist 1965, Urist and Strates 1971). Over
20 BMP ligands have been characterized, which signal through overlapping
combinations of BMP receptors that have unique functions. Postnatally, BMPs
play a critical role in both cartilage and bone development, coordinating both
endochondral and intramembraneous ossification of skeletal elements (Tsumaki
and Yoshikawa 2005, Derynck and Akhurst 2007, Wu, Chen et al. 2016).
Throughout embryonic development BMP signaling plays important roles in
patterning different tissues. During neurulation a dorsally-peaking gradient of
BMP opposes a ventrally-peaking gradient of Shh to pattern the neural tube (Lee
and Jessell 1999). In the developing limb, BMP signaling coordinates apoptosis
of interdigital tissue (Ganan, Macias et al. 1996, Zou and Niswander 1996). One
of the earliest functions of BMP signaling in an organism is to act as a
morphogen to pattern the dorso-ventral (DV) axis (Gourronc, Ahmad et al. 2007,
De Robertis 2008, Tucker, Mintzer et al. 2008, Tuazon and Mullins 2015, Zinski,
Tajer et al. 2018).
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1.1.1: Dorso-ventral patterning
In a process conserved throughout the Animal kingdom, a gradient of
BMP activity forms across the DV axis of an embryo, peaking at the ventral most
point and decreasing dorsally (Zinski, Tajer et al. 2018). This gradient acts to
specify different tissues across the DV axis; high levels of BMP signaling specify
ventral fates, intermediate levels of signaling specify lateral fates, and a lack of
signaling allows specification of dorsal cell fates (Nguyen, Schmid et al. 1998,
Schumacher, Hashiguchi et al. 2011). In the zebrafish, the BMP signaling
gradient begins to form prior to gastrulation and peaks in the mid-gastrula
embryo (Fig 1.1A) (Mintzer, Lee et al. 2001, Tucker, Mintzer et al. 2008, Zinski,
Bu et al. 2017). The DV axis at this stage is distinct from the DV axis in the
patterned embryo due to the cell movements that take place during gastrulation
and neurulation. The dorsal and ventral poles of the 6 hours post fertilization
(hpf) embryo roughly correspond to head and tail tissues of the 24 hpf embryo,
respectively.
Changes in the shape of the BMP signaling gradient during DV patterning
alter tissue patterning (Mullins, Hammerschmidt et al. 1996, Schmid, Furthauer et
al. 2000, Mintzer, Lee et al. 2001, Hammerschmidt and Mullins 2002, Little and
Mullins 2006). Reduction or loss of BMP signaling activity in the developing
embryo causes expansion of dorsal cell fates at the expense of ventral fates, or
dorsalization (Mullins, Hammerschmidt et al. 1996). Over-activation of BMP
signaling results in expansion of ventral fates at the expense of dorsal fates, or
2

ventralization (Nguyen, Schmid et al. 1998, Shen, Little et al. 2009). These DV
patterning phenotypes can be categorized on a 11-point scale with 5 dorsalized
phenotypes (C1-C5), normal DV patterning (WT), and 5 ventralized phenotypes
(V1-V5) (Fig 1.1B). The mildest dorsalization phenotype, C1, is characterized by
a reduction or loss of the ventral tail fin. At the most severe end, the C5
dorsalized phenotype is characterized by radialization of the normally dorsallyrestricted somites. These C5 embryos lyse by 24 hpf due to presumptive
pressure from the radialized somites. The mildest ventralization phenotype, V1,
is characterized by a reduction in the eye and head size, while the most severe
ventralization phenotype, V5, is almost exclusively comprised of tail tissue.

Figure 1.1: Zebrafish dorso-ventral patterning. A) During gastrulation a
gradient of BMP signaling activity specifies the DV axis of the developing
3

embryo. The fully patterned 30 hpf embryo has a distinct DV axis from the one
established during gastrulation. B) Changes in BMP signaling activity during
gastrulation give rise to a series of dose-dependent DV patterning phenotypes in
the 24 hpf embryo. Increases in BMP signaling activity result in expansion of
ventral cell fates at the expense of dorsal fates, or ventralization (V1-V5).
Decreases in BMP signaling result in expansion of dorsal cell fates, or
dorsalization.

1.2.1: The BMP signaling gradient
The BMP signaling gradient is converted to a phosphorylated (p)Smad1/5
gradient by a BMP receptor complex. In the zebrafish, a heterotetramer of two
type I BMP receptors, Acvr1l and Bmpr1, and two type II BMP receptors binds
Bmp2/7 ligand (Fig 1.2) (Bauer, Lele et al. 2001, Mintzer, Lee et al. 2001, Little
and Mullins 2009, Ehrlich, Horbelt et al. 2011, Yadin, Knaus et al. 2016). The
type II receptors phosphorylate the type I receptors at the GS domain (Shi and
Massague 2003, Schmierer and Hill 2007). Phosphorylation results in a
conformational change to the type I BMP receptor which presumably activates it
to then phosphorylate Smad1/5 (Liu, Hata et al. 1996, Feng and Derynck 2005,
Chaikuad, Alfano et al. 2012). pSmad1/5 associates with the coSmad, Smad4,
and translocates to the nucleus where it activates expression of ventral cell fate
specification genes (Hill 2016). A quantifiable pSmad1/5 gradient forms in
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response to BMP signaling activity (Mintzer, Lee et al. 2001, Tucker, Mintzer et
al. 2008, Zinski, Bu et al. 2017, Zinski, Tuazon et al. 2019).
The BMP signaling gradient is regulated by several extracellular and
intracellular antagonists. The extracellular antagonists Chordin, Noggin and
Follistatin all directly inhibit the activity of BMP and play an important role in
shaping the BMP signaling gradient (Nieto 1999, Niehrs 2004, Khokha, Yeh et al.
2005, Dal-Pra, Furthauer et al. 2006). At the level of the receptor the type I BMP
receptor

regulator,

FKBP12,

is

thought

to

stabilize

the

non-signaling

conformation of the type I BMP receptors, and prevent leaky signaling in the
absence of ligand (Chen, Liu et al. 1997, Groppe, Wu et al. 2011, Chaikuad,
Alfano et al. 2012, Machiya, Tsukamoto et al. 2018). Intracellularly, Smad6 and
Smad7 inhibit the activity of pSmad1/5/8 (Hill 2009, Sieber, Kopf et al. 2009,
Song, Estrada et al. 2009). In addition to the direct inhibitors of BMP signaling,
the relative abundance of different TGFb superfamily ligands and receptors are
thought to regulate activity of each other through competition for type II BMP
receptor binding partners (Olsen, Wader et al. 2015, Seher, Lagler et al. 2017,
Wang, Chun et al. 2019). In the following sections, detailed information about the
ligand-receptor components of the BMP signaling complex will be reviewed.

5

Figure 1.2: The BMP ligand-receptor complex that patterns the DV axis of
the developing zebrafish. A receptor heterotetramer composed of two type I
BMP receptors, Acvr1 and Bmpr1, and two type II BMP receptors binds to a
Bmp2/7 heterodimer. Complex assembly allows the type II receptor to
phosphorylate the type I receptor at its GS domain. The kinase of the type I
receptor then phosphorylates Smad1/5.

1.2: The BMP signaling complex
1.2.1: BMP Ligand
BMP ligand is integral for the assembly of BMP receptor complexes and
the initiation of signaling (Allendorph, Vale et al. 2006, Allendorph, Isaacs et al.
2007). The diversity of BMP ligands has been thought to play a role in specifying
6

the activity of BMP receptor complexes (Heinecke, Seher et al. 2009, Little and
Mullins 2009). Studies show that changes in the relative abundance of BMP
ligands results in changes in signaling activity, demonstrating that ligand is
carefully interpreted by the cell (Antebi, Linton et al. 2017).
In the zebrafish, Bmp2/7 is the relevant ligand for patterning the
dorsoventral axis (Little and Mullins 2009). Loss of either Bmp7 or Bmp2 results
in loss of ventral fates, or dorsalization of zebrafish embryos (Dick, Hild et al.
2000, Schmid, Furthauer et al. 2000). Neither Bmp7 nor Bmp2 homodimers can
rescue this loss of patterning, but exogenously provided Bmp2/7 heterodimer
can. Further, it has been shown that the type I BMP receptors Acvr1 and Bmpr1
will not associate with each other in the absence of Bmp2/7 ligand, suggesting
that this ligand is critical for assembly of the BMP signaling complex (Little and
Mullins 2009). The Bmp2/7 heterodimer has unique binding sites with differential
affinity for the type I receptors that are believed to mediate the association of
these two different type I receptors during development.
Another TGFb superfamily ligand, Nodal, also functions during early
gastrulation to pattern the embryo. Nodal signals through Acvr1b and Smad2/3,
and requires the co-receptor One Eye Pinhead to signal (Gritsman, Zhang et al.
1999). In the zebrafish, Nodal is critical for the formation of the dorsal organizer
and Anterioposterior (AP) patterning (Thisse, Wright et al. 2000). During
gastrulation, a marginal gradient of Nodal specifies the mesoderm and
endoderm, and the AP axis. Loss of Nodal in the zebrafish results in loss of
7

mesendodermal structures. Injection of yolk syncytial layer cells in early gastrula
embryos with Activin can rescue loss of Nodal signaling (Gritsman, Zhang et al.
1999).
1.2.2: Type I BMP receptors
There are three highly conserved type I BMP receptors, ACVR1 (also
known as ALK2) BMPR1a (also known as ALK3) and BMPR1b (also known as
ALK6). These receptors are part of the TGFb superfamily and share a functional
resemblance to other type I TGFb receptors. Both BMP and other TGFb Type I
receptors are composed of 5 general domains: The extracellular signal peptide
and ligand binding domains, the transmembrane domain, and the intracellular GS
and kinase domains. While the extracellular domains of these receptors vary
greatly, the intracellular domains are incredibly conserved between different
TGFb family type I receptors and across different species.
The extracellular domains of the type I BMP receptors are important for
ligand interaction. The signal peptide allows localization of these receptors to the
cell membrane, where they are able to contact extracellular BMP ligand and
signal. The cysteine-rich extracellular domain directly interacts with ligand
(Haupt, Deichsel et al. 2014, Hildebrand, Stange et al. 2017). The extracellular
domains are separated from the intracellular domains by a transmembrane
domain that anchors the receptor in the cell membrane.
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The GS domain makes up a small but highly conserved part of the
intracellular domain. Within the GS domain are several serines and threonines,
including a Glycine-Serine (GS) motif, for which the domain is named (Franzen,
Heldin et al. 1995, Wieser, Wrana et al. 1995, Attisano, Wrana et al. 1996).
These serines and threonines are phosphorylated by the kinase of type II
receptors (Shi and Massague 2003, Schmierer and Hill 2007). Phosphorylation of
this domain results in a conformational change to ACVR1 that displaces the
regulator FKBP12 and allows ATP and Smad to bind the receptor (Liu, Hata et al.
1996, Feng and Derynck 2005, Chaikuad, Alfano et al. 2012). The ACVR1 kinase
domain then phosphorylates its substrate Smad1/5.
1.2.3: ACVR1
Mutations to the type I receptor ACVR1 are associated with human
disease. Fibrodysplasia ossificans progressive (FOP) is caused by activating
mutations to ACVR1, which lead to downstream overactivation of the BMPpSmad1/5 signaling pathway (Shore, Xu et al. 2006, Kaplan, Xu et al. 2009).
Alternatively, loss of function mutations in ACVR1 have been associated with
congenital heart defects (Smith, Joziasse et al. 2009, Joziasse, Smith et al.
2011). The different organs affected by alteration of signaling by ACVR1 highlight
the importance of BMP signaling in multiple systems.
In the developing zebrafish, acvr1l (the functional ortholog of human
ACVR1 (Yelick, Abduljabbar et al. 1998)) is required for DV patterning (Bauer,
Lele et al. 2001, Mintzer, Lee et al. 2001). A genetic loss of function mutant of
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acvr1l, lost-a-fin (laf), is characterized by a complete lack of specification of
ventral cell fates (Mintzer, Lee et al. 2001). Maternally provided ACVR1 is not
sufficient to pattern the embryo, as exemplified by the C2 phenotype of zygotic
mutants. The laf mutant can be rescued by introduction of human ACVR1 mRNA
into a 1-cell embryo, demonstrating the conserved activity of this receptor across
species (Shen, Little et al. 2009). In addition, misexpression of ACVR1 containing
the causative FOP mutation results in ventralization (Shen, Little et al. 2009),
demonstrating that this mutant overactivity is also conserved between species.
ACVR1 activity in the context of FOP will be a central focus in the following
chapters.
1.2.4: BMPR1
In most cases, the activity of BMPR1a and BMPR1b is redundant (WineLee, Ahn et al. 2004, Yoon, Ovchinnikov et al. 2005). Loss of Bmpr1a and
Bmpr1b in the mouse results in severe chondrodysplasia and impaired
endochondral ossification. In humans, BMPR1a loss of function mutations have
been associated with both heart disease and juvenile polyposis syndrome
(Handra-Luca, Condroyer et al. 2005, Demal, Heise et al. 2019). Constitutively
active BMPR1a induces severe skeletal malformation, including fusion of the
joints. Interestingly however, unlike ACVR1, BMPR1 overactivity does not induce
heterotopic ossification, demonstrating that these receptors have distinct roles in
skeletal and connective tissue development (Kobayashi, Lyons et al. 2005).
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In the zebrafish, BMPR1 is also required for dorsoventral axial patterning.
Loss of Bmpr1a results in embryos that are dorsalized to a C4 phenotype (data
shown in Chapter 2). Loss of Bmpr1b alone does not appear to affect DV
patterning in a wild-type embryo, but it further dorsalizes Bmpr1a mutants to a C5
phenotype, indicating that it does have some ability to pattern the embryo.
Interestingly, overexpression of acvr1l does not affect DV patterning of
developing zebrafish, but bmpr1 overexpression results in dominant negative
inhibition of signaling and dorsalization (Ben Tajer, unpublished results).
1.2.5: Type II BMP receptors
Unlike the type I BMP receptors, some of the type II BMP receptors are
not specific to BMP signaling. The three type II receptors, BMPR2, ACVR2a and
ACVR2b. ACVR2a and ACVR2b are shared by the Activin/Nodal signaling
complex, another TGFb superfamily signaling complex (Attisano, Wrana et al.
1996). Type II receptors play an important role in activation of the signaling
complex (Wrana, Attisano et al. 1994, Attisano, Wrana et al. 1996). They are
constitutively active Serine/Threonine kinases that phosphorylate the type I
receptors at the GS domain to activate them.
Data support that ligand binding is required to bring the type II receptors in
proximity of the type I receptors to allow this phosphorylation to occur (Attisano,
Wrana et al. 1996, Allendorph, Vale et al. 2006, Allendorph, Isaacs et al. 2007).
The order of receptor assembly within the BMP complex has not been
determined in the context of DV patterning. BMPR1 binds ligand with high affinity
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on its own and has been shown to assemble in homomeric complexes poised to
respond to ligand (Allendorph, Isaacs et al. 2007, Heinecke, Seher et al. 2009,
Marom, Heining et al. 2011). Conversely, TGFb signaling is initiated by ligandbound type II receptors cooperatively recruiting the type I receptors into the
complex (Greenwald, Groppe et al. 2003, Groppe, Hinck et al. 2008).
The proportions of ACVR2 and BMPR2 has been suggested to bias
signaling in response to different ligands. In multiple myeloma cells, the
abundance of BMPR2 and ACVR2 determines if ACVR1 signals in response to
BMP or Activin ligand, respectively (Olsen, Wader et al. 2015, Olsen, Sankar et
al. 2018). In addition, TGFb superfamily signaling activity appears to be regulated
by relative abundance of different receptor components due to competition for
type II receptors (Olsen, Wader et al. 2015, Seher, Lagler et al. 2017, Wang,
Chun et al. 2019).
Both BMPR2 and ACVR2b have been shown to play important but
redundant roles in osteoblast differentiation in vitro (Liu, Zhang et al. 2012). Type
II receptor mutants have not been characterized in the zebrafish, although
knockdown studies suggest that BMPR2 is important for left right patterning
(Monteiro, van Dinther et al. 2008) and ACVR2 is important for craniofacial
development (Albertson, Payne-Ferreira et al. 2005). In addition, Activin, another
TGFb superfamily ligand, signaling though ACVR2a has been shown to be
important for both fin and heart regeneration in the adult zebrafish (Dogra, Ahuja
et al. 2017).
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1.3: Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP) is a debilitating disease
characterized by malformation of the developing skeleton and formation of bone
in extraskeletal sites, or heterotopic ossification (HO). FOP occurs in about 1 in
1.5million people, but as the most severe disorder of HO, it is a good model for
other genetic and non-genetic disorders of HO. FOP is caused by activating
mutations to the type I BMP receptor, ACVR1 (Shore, Xu et al. 2006, Kaplan, Xu
et al. 2009). These mutations over-activate downstream BMP-pSmad1/5
pathway signaling activity (Fukuda, Kohda et al. 2009, Shen, Little et al. 2009,
Shore and Kaplan 2011). Currently there is no specific treatment for this disease,
but work is being done to determine the changes to signaling activity in FOPACVR1 to better identify an effective therapeutic target.
1.3.1: Mutations
All causative mutations of FOP occur either within the GS domain or the
kinase domain of ACVR1 (Fig 1.3A). There does not appear to be a correlation
between severity and the domain location of the mutation, but some mutations do
appear to be consistently more severe than others (Kaplan, Xu et al. 2009,
Haupt, Xu et al. 2018). Given the low prevalence of the disease however, it is
unclear if these trends are due to actual differences in mutation effect or
individual patient variance.
Over 95% of FOP cases are caused by the same amino acid substitution within
the GS domain, R206H (Shore, Xu et al. 2006). This mutation occurs just
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downstream of the phosphorylation sites within the GS domain, and it has been
speculated that this mutation acts as a phospho-mimetic (Groppe, Shore et al.
2007). Interestingly, this mutation also is frequently found in childhood pontine
gliomas, tumors within the white matter of the pons, which do not exhibit HO
(Hoeman, Cordero et al. 2019).
Four variant FOP mutations within the GS domain of ACVR1 have been
characterized: L196P, P197-F198 del ins, R202I, and Q207E (Kaplan, Xu et al.
2009, Ohte, Shin et al. 2011, Haupt, Deichsel et al. 2014, Haupt, Xu et al. 2018).
Additionally, a non-naturally occurring constitutively active ACVR1 can be
generated with a Q207D substitution and causes severe heterotopic ossification
in a knock-in mouse model (Agarwal, Loder et al. 2015). In the kinase domain
there are six characterized mutants: R258S, R258G, G328E, G328R, G328W,
G356D, and R375P (Fukuda, Kanomata et al. 2008, Kaplan, Xu et al. 2009,
Kaplan, Kobori et al. 2015, Haupt, Xu et al. 2018). While these mutations occur
relatively far apart on the secondary structure of ACVR1, analysis of the tertiary
structure reveals most FOP mutations occur on the same face of the intracellular
domain (Fig 1.3B) (Kaplan, Xu et al. 2009).
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Figure 1.3: Causative mutations of FOP. A) Five mutations have been
characterized that occur within the GS domain and six mutations have been
characterized that occur within the kinase domain. B) Three-dimensional
structure of the intracellular domain of ACVR1. Most mutations occur on the
same face of the receptor (big circle); only two mutants, G356D and R375P,
occur in a different area (small circle).

1.3.2: Clinical symptoms
FOP is characterized by two clinical features, skeletal malformations and
progressive heterotopic ossification (HO). Altered patterning during skeletal
development results in skeletal malformations particularly within joints.
Pathognomonic malformation of the great toes occurs in most cases of FOP and
is sufficient to diagnose a patient (Kaplan, Xu et al. 2008). Malformation of the
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thumbs and cervical spine are also commonly reported (Schroeder and Zasloff
1980). These skeletal defects tend to be relatively mild, but may contribute to the
progression of HO.
Progressive HO usually begins in childhood and progresses throughout
life. HO lesions commonly form within muscle tissue but have also been found to
form in other musculoskeletal soft connective tissues such as tendons and
ligaments (McKusick 1972). In FOP, HO occurs through an endochondral
process, much like the growth plates within developing bone (Gannon, Kaplan et
al. 1997, Shore and Kaplan 2010). Within FOP patients, two types of HO
initiation have been identified: spontaneous and injury induced.
In response to injury and prior to the onset of endochondral ossification,
inflammation is associated with a massive influx of fluid resulting in painful
swellings often referred to as “flare-ups” (Kaplan, Tabas et al. 1993). Similar to
early stages of normal tissue healing in response to injury, flare-ups are
preceded

by

cell

death

within

the

affected

tissue

and

subsequent

fibroproliferation (Gannon, Valentine et al. 1998, Pignolo, Suda et al. 2005, Shore
and Kaplan 2010). However, in the case of HO formation in FOP, within the
fibroproliferative area a cartilage-like matrix is deposited which will act as a
scaffold for endochondral ossification (Convente, Chakkalakal et al. 2018, Haupt,
Stanley et al. 2019).
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Spontaneous HO formation is less well characterized and it is unclear if it
is truly spontaneous or if it is incited by undetected inflammation. Like injuryinduced HO, spontaneous HO can be preceded by a flare-up, especially in young
children. It often occurs in a characteristic anatomic progression throughout life,
first affecting the axial skeleton and later in life progressing to the appendicular
skeleton (Connor and Evans 1982, Pignolo, Bedford-Gay et al. 2016). Eventually,
regardless of mode of initiation, the cumulative HO leads to progressive
immobilization of patients and in many cases death by thoracic insufficiency.
Heterotopic ossification is not unique to FOP. It has been shown to occur in
response to severe traumatic injury including spinal and head trauma, blast
injury, burns, and joint surgery (Cohn, Schwarzkopf et al. 2011, Alfieri, Forsberg
et al. 2012, Ranganathan, Loder et al. 2015, Dey, Wheatley et al. 2017).
Although mutations to ACVR1 are not a factor in these cases (Amalfitano, Fyfe et
al. 2018), many of the stages of progression are the same, including the
formation of bone through an endochondral pathway (de Vasconcellos, Zicari et
al. 2019). HO formation through Intramembranous bone formation also occurs
with some trauma and another genetic disease of HO, progressive osseous
heteroplasia (POH) (Ware, Brewer et al. 2019). Research into FOP pathogenesis
and treatment provide insight into HO in other diseases along with normal bone
formation itself.
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1.3.2: Treatments
The current standard of treatment for patients with FOP is administration
of corticosteroids to reduce inflammation. However, long term use of steroids is
associated with several debilitating conditions including thinning of connective
tissues especially the skin, osteoporosis, and iatrogenic Cushing’s syndrome
(Buchman 2001). While these medications can be very helpful in alleviating the
symptoms of FOP, including reducing severity of flare-ups, a more directed
treatment is needed (Cappato, Giacopelli et al. 2018).
Clinical trials are ongoing including for ACVR1-specific inhibitors and a
retinoic acid receptor agonist, Palovarotene (Yu, Deng et al. 2008, Mohedas,
Wang et al. 2014, Chakkalakal, Uchibe et al. 2016, Medicine 2019). The ACVR1specific inhibitors are related to the first type I BMP inhibitor to be characterized,
dorsomorphin (Yu, Hong et al. 2008). They act to competitively inhibit ATP
binding to ACVR1, preventing the kinase domain from phosphorylating Smad1/5
(Mohedas, Xing et al. 2013, Sanvitale, Kerr et al. 2013, Williams and Bullock
2018). Retinoic acid receptor agonists like Palovarotene have been shown to
block chondrogenesis in vivo, preventing subsequent endochondral ossification
of tissue (Chakkalakal, Uchibe et al. 2016, Sinha, Uchibe et al. 2016). Both these
potential treatments represent promising targeted treatments for FOP patients.
Recently, FOP-ACVR1 was shown to acquire the ability to signal in
response to the TGF-beta ligand Activin A (Hatsell, Idone et al. 2015, Hino, Ikeya
et al. 2015, Lees-Shepard, Nicholas et al. 2018). This acquired signaling ability
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has been proposed as a causative factor in HO formation, and in fact an Activin
A antibody prevents injury induced HO formation in an inducible FOP mouse. A
mouse model of FOP revealed that chemokine expression and immune cell
infiltration are altered in FOP and specific depletion of macrophages and mast
cells can prevent HO progression in FOP (Convente, Chakkalakal et al. 2018),
and potential FOP-relevant targets for Activin A inhibition have been suggested
in the inflammatory process of HO formation (Kaplan, Pignolo et al. 2016, Kan,
Yang et al. 2019).
1.4: Models of FOP
(Adapted from (Convente, Towler et al. 2017))
Integral to learning how ACVR1-R206H causes FOP and how it can be treated
are animal models of the disease. The evolutionarily conserved BMP signaling
pathway is studied in several highly informative animal models including fruit flies
(Drosophila melanogaster) and zebrafish (Danio rerio), providing important
insight into the cellular and molecular mechanisms of BMP signaling and the in
vivo activities of the ACVR1receptor or its orthologs in vivo (Eivers, Demagny et
al. 2009, Moustakas and Heldin 2009, Wharton and Derynck 2009). BMP
signaling in mammalian systems has been examined predominantly in the mouse
to investigate its molecular mechanisms and developmental consequences
(Kamiya and Mishina 2011).
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1.4.1: Drosophila and Mutations in Sax
The BMP pathway is highly evolutionarily-conserved (Lowery, Pazin et al.
2011) and although flies do not form bone, D. melanogaster (fruit fly) has the
ligand and receptor components of the BMP signaling pathway (Ray and
Wharton 2001, Affolter and Basler 2007). Mutations in saxophone (sax), a
Drosophila BMP type I receptor gene that is the homologue of the human
ACVRL1/ALK1 and ACVR1/ALK2 receptors, have been identified and examined
for effects on BMP signaling and in vivo function (Twombly, Bangi et al. 2009). A
sax G412E mutation (sax2) occurring in the amino acid corresponding to ACVR1
codon 356 (which is mutated in some FOP variants) participates in BMP receptor
complexes and produces elevated signaling (Twombly, Bangi et al. 2009).
Expression of human ACVR1-R206H within a developing fly results in loss of
wing vasculature consistent with over-activation of the BMP signaling pathway
(Le and Wharton 2012), demonstrating that this over-activity is conserved within
Drosophila.
1.4.2: Zebrafish Models and the Acvr1l Receptor
The zebrafish embryonic development model is ideal for high throughput
screens of signaling changes and potential treatments (Spoorendonk, Hammond
et al. 2010, Huang, Nguyen et al. 2011). The chemical compound dorsomorphin,
a small molecule inhibitor of all BMP type I receptors (ACVR1, BMPR1a, and
BMPR1b), was identified by in vivo screening for effects on zebrafish embryonic
dorsal-ventral patterning (Yu, Deng et al. 2008). More specific small molecule
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inhibitors that selectively target single BMP type I receptors, including ACVR1,
have been developed in recent years (Mohedas, Xing et al. 2013, Sanvitale, Kerr
et al. 2013). Early zebrafish expression is easily manipulated using single cell
zygote microinjection. mRNA or DNA can be introduced to overexpress certain
genes, while morpholinos can be used to knock down expression (Nasevicius
and Ekker 2000). Furthermore, transgenic zebrafish models also have great
potential as a system to investigate bone and skeletal development and
formation of heterotopic bone (Collery and Link 2011, Kan and Kessler 2011).
Investigations using zebrafish embryos have demonstrated that a BMP
signaling gradient is critical for patterning cell fates during establishment of
dorsal-ventral polarity, with high levels of BMP signaling inducing ventral
tissues/structures and low levels inducing dorsal structures in vertebrates
(Langdon and Mullins 2011). Zebrafish embryos develop dose-dependent
phenotypes in response to changes in BMP signaling (Little and Mullins 2006,
Yu, Deng et al. 2008, Little and Mullins 2009). Developing zebrafish embryos
therefore provide a sensitive assay for perturbations in the BMP signaling
gradient by evaluating dorsal-ventral patterning.
Zebrafish Acvr1l, the paralog of human ACVR1, is a BMP type I receptor
required for signaling during dorsal-ventral axis formation (Little and Mullins
2006). Injection of mutant ACVR1-R206H mRNA into acvr1l null embryos
induced a severely ventralized phenotype (absence of head structures), and
over-activates pSmad1/5 signaling (Shen, Little et al. 2009). In addition the
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variant mutation ACVR1-G328R has also been shown to over-activate the BMP
signaling pathway in zebrafish (Mucha, Hashiguchi et al. 2018). These results
provided the first in vivo evidence that the ACVR1-R206H mutation leads to
overactivation of the BMP-pSmad1/5 signaling pathway.
While zebrafish embryonic development is an excellent model for
characterizing changes in BMP signaling, an adult zebrafish model of HO would
be ideal to study the pathogenesis of FOP. Because ACVR1-R206H mediated
embryonic ventralization is not compatible with survival, an inducible system is
necessary for analysis in an adult. A heat-shock-inducible Acvr1l-Q207D fish has
been developed and characterized (LaBonty, Pray et al. 2017). Q207D is a nonnaturally occurring mutation that results in constitutive activity by ACVR1. A
naturally-occurring variant FOP mutation does occur at that site however,
Q207E. Q207D induces ventralization of zebrafish embryos indicating that the
mutation is over-activating BMP signaling in the fish. In adult fish, the Q207D
mutation appears to induce mild skeletal malformation, most notably scoliosis,
similar to the malformations observed in human patients and mouse models. It is
unclear, however, if these fish form HO lesions. While they appear to have sites
of fibroproliferation, they do not appear to form bone in response to injury or
ligand stimulation (LaBonty, Pray et al. 2018). It is possible that the regenerative
features of the fish are protective against the formation of HO or that the nonsustained, periodic expression of this activated receptor as induced with the
heat-shock promoter in these studies is insufficient to induce HO. Ectopic BMP
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ligand has been shown to produce bony lesions in mammals, but this has not
been tested in fish (Urist 1965).
1.4.3: Genetically-Engineered Mouse Models
Knock-in mouse models of FOP have been integral for characterizing the
skeletal malformations and progressive heterotopic bone formation that occurs in
this disease. A constitutive knock-in mouse for ACVR1-R206H showed that mice
chimeric for the FOP mutation exhibit the same clinical features as patients with
FOP, including skeletal malformations as well as spontaneous and injury induced
HO (Chakkalakal, Zhang et al. 2012). In addition, histological analyses of regions
undergoing heterotopic ossification demonstrated the same progression of
cellular events as observed in patient lesions, including inflammation-associated
catabolism of connective tissues followed by a robust anabolic tissue
replacement by cartilage and bone. Germline transmission of the ACVR1-R206H
mutation is not compatible with survival in the mouse, as in the zebrafish, so
models in which ACVR1-R206H is inducible or expressed in restricted domains
have been developed (Chakkalakal, Zhang et al. 2012, Hatsell, Idone et al. 2015,
Chakkalakal, Uchibe et al. 2016).
Recently a conditional knock-in mouse (Acvr1cR206H/+) with expression of
Acvr1R206H controlled by Cre-inducible recombination has been reported (Hatsell,
Idone et al. 2015, Chakkalakal, Uchibe et al. 2016). The conditional Acvr1R206H
mouse model allowed for cell-specific expression of the R206H mutation. This
conditional knock-in mouse has allowed extensive characterization of injury23

induced HO. Mice expressing the R206H mutation only in limb mesenchymal
progenitor cells (Prrx1+) formed skeletal malformations similar to those seen in
patients, due to altered chondrocyte development in the growth plates of long
bones,

and

developed

spontaneous

heterotopic

ossification

postnatally

(Chakkalakal, Uchibe et al. 2016). The knock-in mouse has also been important
for characterizing the progression of HO lesions in FOP, mainly through an
injury-induce HO induction model. In particular, studies of HO lesion progression
in these mice found elevated and sustained immune cell infiltration compared to
control mice (Convente et al. 2017). Further, inflammatory cytokines are
increased with sustained expression at these sites of inflammation. Interestingly,
depletion of mast cells or macrophages greatly ameliorated the progression of
Acvr1R206H-induced HO, demonstrating that inflammation is an important inciting
factor to the formation of HO.
1.4.4: Non-Genetic, Injury-Induced Models of Heterotopic Ossification
An inflammatory component is a common feature among most nongenetic incidences of heterotopic ossification (Convente, Wang et al. 2015).
Development of HO following joint arthroplasty (Freeman, Parvizi et al. 2010,
Cohn, Schwarzkopf et al. 2011), combat blast injury (Alfieri, Forsberg et al. 2012,
Evans, Forsberg et al. 2012), burn (Potter, Forsberg et al. 2010), and
tendon/ligament injury and reconstruction (Erdil, Asik et al. 2012, O'Brien, Frank
et al. 2012, Bhandary, Shetty et al. 2013, Camillieri, Di Sanzo et al. 2013,
Andrachuk, Scillia et al. 2016) occurs with moderate frequency, with estimates as
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high as 65% for select pathologies (Potter, Forsberg et al. 2010). Significant
efforts have recently focused on developing animal models replicating these nongenetic, injury-induced episodes of HO to better understand disease etiology and
assist with candidate drug testing. A combination burn/tenotomy HO murine
model was recently developed (Peterson, Agarwal et al. 2015) and has already
been used to identify SMAD7, a BMP signaling antagonist protein, as a factor
that prevents HO formation in Achilles tendon injury (Zhang, Zhang et al. 2016).
Additionally, a recently developed combat blast rat model of HO (Polfer, Hope et
al. 2015) will be useful for investigating severe trauma-induced HO development.
1.4.5: Naturally Occurring Animal Models of Heterotopic Ossification
Bone formation similar to FOP lesions in humans has been reported in
both cats and dogs (Seibold and Davis 1967, Warren and Carpenter 1984,
Valentine, George et al. 1992, Kaplan, Shore et al. 2005, Yabuzoe, Yokoi et al.
2009). Histopathological analyses of affected animals showed extensive
fibroproliferation and endochondral bone formation. In particular, several cats
were also identified with malformation of digit 1, as observed in human patients.
Genetic analysis of two cats determined that their FOP-like disease was caused
by the same ACVR1-R206H mutation that is responsible for FOP in most human
patients (Casal, Engiles et al. 2019).
Several reports have documented an unusual ocular heterotopic
ossification in guinea pigs (Griffith, Sassani et al. 1988, Brooks, McCracken et al.
1990, Williams and Sullivan 2010). The HO appears as a white lesion at the
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limbus which corresponds to new bone formation in the ciliary body of the eye
and was initially reported as osseous choristoma (Brooks, McCracken et al.
1990, Williams and Sullivan 2010). The heterotopic bone formation includes
formation of bone marrow and marrow elements within the ciliary bodies (Griffith,
Sassani et al. 1988).
1.5: FOP and the BMP signaling complex
While the phenotypic consequences of FOP have been well characterized,
the mechanism by which the FOP mutation leads to overactive signaling requires
more elucidation. Several cell-culture studies have found that FOP-ACVR1
exhibits altered ligand receptor affinity (Shen, Little et al. 2009, Le and Wharton
2012, Haupt, Deichsel et al. 2014, Hatsell, Idone et al. 2015, Hino, Ikeya et al.
2015, Hino, Horigome et al. 2017, Lees-Shepard, Yamamoto et al. 2018), which
may contribute to its aberrant activity. Characterization of changes in ACVR1BMP receptor complex signaling will allow for the development of more targeted
therapies and give insight into how the BMP ligand-receptor complex normally
signals.
1.5.1: Ligand
Previous work by our lab discovered that ACVR1-R206H retained the
ability to ventralize zebrafish in the absence of both Bmp2 and Bmp7 (Shen,
Little et al. 2009). These data suggested that the FOP-ACVR1 mutant was
constitutively active. Interestingly, ACVR1-R206H was shown to be able to signal
without a ligand binding domain in both cell culture and Drosophila (Le and
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Wharton 2012, Haupt, Deichsel et al. 2014, Hildebrand, Stange et al. 2017,
Haupt, Xu et al. 2018). FOP-ACVR1 has still been shown, however, to induce
hyperactive signaling in the presence of BMP ligand (Billings, Fiori et al. 2008,
Fukuda, Kanomata et al. 2008, Chaikuad, Alfano et al. 2012, Haupt, Xu et al.
2018), supporting that the mutant receptor has both ligand-independent activity
and ligand-responsive hyperactivity.
Recent in vitro studies have shown that FOP-ACVR1 has acquired the
ability to phosphorylate Smad1/5 in response to the TGFb superfamily ligand,
Activin A, which normally binds ACVR1b and signals through Smad2/3 (Hatsell,
Idone et al. 2015, Hino, Ikeya et al. 2015, Dogra, Ahuja et al. 2017, LeesShepard, Yamamoto et al. 2018, Wang, Shore et al. 2018). Activin A is a
homodimeric ligand composed of two inhibinba monomers. While Activin A is not
considered a BMP ligand, it belongs to the TGFb superfamily and has been
shown to compete with BMP ligand for ACVR2 binding (Olsen, Wader et al.
2015). Recent in vitro studies have also suggested that Activin A may weakly
stimulate pSmad1/5 signaling (Wang, Shore et al. 2018). In the Xenopus embryo,
Activin plays an important role in anterio-posterior patterning and mesoderm
induction of embryos (Dohrmann, Hemmati-Brivanlou et al. 1993). In the
Zebrafish, Activins are not known to play a role in patterning, but they can rescue
loss of nodal signaling (Gritsman, Zhang et al. 1999).
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The zebrafish genome encodes two homologs of InhibinbA, Inhibinbaa
and Inhibinbab. An RNAseq study by our lab showed that neither Inhibinbaa nor
Inhibinbab is maternally deposited within the zebrafish egg (Ricardo Fuentes,
unpublished data). By wholemount in situ hybridization analysis, inhibinbaa
expression starts around late gastrulation when it is expressed at low levels in
the prechordal plate; as development progresses Activin A becomes expressed
in the hatching gland and then the pharyngeal arches of the zebrafish larvae
(Thisse, Heyer et al. 2004). RT-PCR detects low levels of inhibinbaa expression
during early gastrulation (Hashiguchi, Shinya et al. 2008), while by RNAseq
inhibinbaa is not expressed until the 4-8 somite stage, and inhibinbab is not
expressed until the protruding mouth stage (White, Collins et al. 2017).
No zebrafish Activin A mutant has been characterized to date, although
the Activin B mutant (inhbbsa70) exists and appears to have no developmental
defects (Busch-Nentwich, Kettleborough et al. 2013). In the adult zebrafish,
Activin A plays an important role in both heart and fin regeneration, and inhibition
or knockdown of Activin A impairs both of these processes (Jazwinska, Badakov
et al. 2007, Dogra, Ahuja et al. 2017). Activin A signaling also plays an important
role in the developing gonad of the zebrafish, where it contributes to oocyte
maturation by paracrine signaling (Wu, Patel et al. 2000, DiMuccio, Mukai et al.
2005).
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1.5.2: Type I and II BMP receptors
Previous work in cell culture has shown that loss of BMPR1a or BMPR1b
individually has no effect on the signaling activity of ACVR1-R206H (Hino, Ikeya
et al. 2015). Given that the activity of BMPR1a and BMPR1b is largely redundant
however (Wine-Lee, Ahn et al. 2004, Yoon, Ovchinnikov et al. 2005), each may
be able to compensate for the loss of the other. The ability of ACVR1-R206H to
function in the absence of both BMPR1a and BMPR1b has not been tested.
Since BMPR1 is critical to DV patterning in the zebrafish and development of
cartilage and bone (Yoon, Ovchinnikov et al. 2005), it would be surprising if
ACVR1 gained the ability to signal in its absence.
Work in cell culture also showed that knocking down ACVR2a and BMPR2
individually abrogated signaling activity by ACVR1-R206H (Bagarova, Vonner et
al. 2013, Hino, Ikeya et al. 2015). Knocking down both receptors in conjunction
resulted in loss of all signaling by ACVR1-R206H. Interestingly however, the loss
of activity by ACVR1-R206H in a BMPR2, ACVR2a KD could be rescued with the
extracellular domains of the type II receptors alone (Bagarova, Vonner et al.
2013). These data suggest that, at least in the case of signaling by FOP-ACVR1,
the kinase activity of the type II receptors is dispensable. As discussed above,
however, FOP-ACVR1 still requires Serine and Threonine residues in its GS
domain to signal, supporting that phosphorylation is still important for its
activation. In this case phosphorylation by BMPR1 or autophosphorylation by
ACVR1 itself was implicated (Bagarova, Vonner et al. 2013).
29

Since ligand is thought to facilitate the association of type I and II BMP
receptors to initiate signaling (Wrana, Attisano et al. 1994, Attisano, Wrana et al.
1996, Allendorph, Vale et al. 2006, Little and Mullins 2009), ligand-independent
signaling by FOP-ACVR1 suggests that the mutant receptor would also signal
independently of receptor complex formation. The changes in FOP-ACVR1
ligand receptor requirements highlight that much remains to be elucidated about
how the BMP ligand-receptor complex assembles and signals. The following
chapters describe our work using zebrafish DV patterning as a model to further
explore the changes in signaling complex requirements and activity of mutant
FOP-ACVR1.
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CHAPTER 2: Fibrodysplasia Ossificans Progressiva mutant
ACVR1 Signals by Multiple Modalities
2.1: Summary
Fibrodysplasia ossificans progressiva (FOP) is a rare human genetic
disorder caused by activating mutations in the type I BMP/TGFβ cell surface
receptor, ACVR1. These mutations over-activate signaling through phosphoSmad1/5 (pSmad1/5), resulting in altered skeletal development and progressive
heterotopic ossification. To investigate the uncertain mechanism by which FOPACVR1 enhances pSmad1/5 activation, we used zebrafish embryonic
dorsoventral (DV) patterning as an assay for BMP signaling. We determined that
the FOP mutants ACVR1-R206H and -G328R do not require their ligand binding
domain to over-activate BMP signaling in DV patterning. However, intact ACVR1R206H and G328R have the ability to respond to ligand. Additionally, BMPR1, a
type I BMP receptor normally required for BMP-mediated patterning of the
embryo, is dispensable for both ligand-independent BMP signaling activation and
ligand-responsive BMP signaling hyperactivation by ACVR1-R206H. These
results demonstrate that FOP-ACVR1 is not constrained by the same type I
receptor and ligand partner requirements as WT-ACVR1.
2.2: Introduction
Fibrodysplasia ossificans progressiva (FOP) is a rare human genetic
disorder characterized by altered skeletal development and extraskeletal bone
formation. Patients with FOP have pathognomonic malformation of the great toes
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and progressive spontaneous and injury-induced heterotopic ossification (HO)
that eventually leads to loss of mobility (Connor and Evans 1982, Cohen, Hahn
et al. 1993, Kaplan, Xu et al. 2009). Most cases of FOP are caused by a single
amino acid substitution, R206H, in the type I BMP/TGFβ cell surface receptor
ACVR1 (also known as ALK2), which over-activates signaling through phosphoSmad1/5 (pSmad1/5) (Shore, Xu et al. 2006, Fukuda, Kohda et al. 2009, Shen,
Little et al. 2009, van Dinther, Visser et al. 2010). A small subset of patients with
variant presentation of the classical FOP phenotype have distinct activating
mutations in the ACVR1 gene, including the substitution G328R (Kaplan, Xu et
al. 2009, Haupt, Xu et al. 2018). While the phenotypic consequences of
increased ACVR1 signaling have been well characterized in both patients and
animal models (Pignolo, Shore et al. 2011, Casal, Engiles et al. 2019,
Chakkalakal and Shore 2019), the mechanism by which these mutations lead to
over-active signaling is less well understood.
ACVR1 and its signaling partners belong to the transforming growth factor
beta (TGFb) superfamily. The activity of ACVR1 is critical to several
developmental processes including embryonic patterning and skeletal formation
(Little and Mullins 2006, Derynck and Akhurst 2007). In the presence of ligand,
ACVR1 complexes with other BMP receptors to signal. In zebrafish, Acvr1l (also
known as Alk8), the zebrafish paralog to human ACVR1 and mouse ACVR1
(Yelick, Abduljabbar et al. 1998), forms a tetrameric receptor complex with one
other type I BMP receptor, Bmpr1a or Bmpr1b (also known as Alk3 and Alk6
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respectively), and two type II BMP receptors (Little and Mullins 2006, Ehrlich,
Horbelt et al. 2011, Yadin, Knaus et al. 2016). Receptor complex assembly
allows the type II BMP receptors to phosphorylate the type I receptors at
serine/threonine residues within the GS domain (Shi and Massague 2003,
Schmierer and Hill 2007). Phosphorylation of the type I BMP receptors results in
a conformational change, allowing them to bind ATP and phosphorylate Smad1/5
to initiate downstream transcription (Liu, Hata et al. 1996, Feng and Derynck
2005, Chaikuad, Alfano et al. 2012).
The zebrafish embryo is an excellent genetically tractable in vivo model for
investigating the signaling mechanism of the ACVR1-FOP receptor (Shen, Little
et al. 2009, Mucha, Hashiguchi et al. 2018). In the early zebrafish embryo, BMP
acts as a morphogen to pattern the dorsoventral (DV) axis in a process that is
conserved throughout the animal kingdom (Zinski, Tajer et al. 2018). High levels
of BMP signaling specify ventral cell fates and intermediate signaling specifies
lateral fates, while absence of signaling allows dorsal cell fate specification.
Perturbations to this BMP signaling gradient in the developing embryo result in
distinct, dose-dependent patterning phenotypes (Fig 2.1.1G). Over-activation of
the BMP signaling pathway by FOP-ACVR1 results in ventralization, an excess
of ventral cell fate specification at the expense of dorsal fates (Shen, Little et al.
2009, Mucha, Hashiguchi et al. 2018), while loss of endogenous acvr1l
expression leads to an opposite dorsalization. Loss of acvr1l in the zebrafish can
be rescued by human ACVR1, demonstrating their conserved activity (Shen,
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Little et al. 2009). The DV pattern is generated through a quantifiable pSmad1/5
signaling gradient within the gastrulating embryo that peaks ventrally and
decreases dorsally (Mintzer, Lee et al. 2001, Little and Mullins 2006, Tucker,
Mintzer et al. 2008, Zinski, Bu et al. 2017, Zinski, Tuazon et al. 2019).
Previous work by our lab demonstrated that misexpression of ACVR1R206H mRNA in the zebrafish embryo over-activates BMP signaling in the
absence of Bmp2 and Bmp7, the obligatory patterning ligands of the developing
zebrafish (Nguyen, Schmid et al. 1998, Dick, Hild et al. 2000, Schmid, Furthauer
et al. 2000, Little and Mullins 2009, Shen, Little et al. 2009). Surprisingly,
ACVR1-R206H shows acquired responsiveness to novel ligands; most notably
Activin A, a TGFb superfamily ligand that normally signals through ACVR1b and
pSmad2/3 (Hatsell, Idone et al. 2015, Hino, Ikeya et al. 2015, Lees-Shepard,
Yamamoto et al. 2018). While ACVR1-R206H has been shown to require its
normal type II BMP receptor partners, BMPR2 and ACVR2a (Bagarova, Vonner
et al. 2013, Hino, Ikeya et al. 2015), it is unknown whether it still requires its type
I BMP receptor partner, BMPR1. ACVR1-R206H has been shown to signal in the
absence of BMPR1a or BMPR1b individually (Hino, Ikeya et al. 2015). However,
the ability of FOP-ACVR1 to function in the absence of both BMPR1a and
BMPR1b, which largely function redundantly (Wine-Lee, Ahn et al. 2004, Yoon,
Ovchinnikov et al. 2005), has not been tested.
In this study, we used BMP-pSmad1/5 dose-dependent DV patterning of
the developing zebrafish to assay for signaling activity of ACVR1-R206H and
34

ACVR1-G328R in vivo. We show that ligand-binding domain deficient ACVR1R206H and -G328R can over-activate pSmad1/5 signaling, demonstrating that
these mutant receptors have enhanced signaling activity in the absence of ligand
binding. However, both ACVR1-R206H and -G328R FOP mutants also exhibit
hyperactive signaling in response to ligand. We further determined that neither
the ligand-independent nor the ligand-responsive signaling modalities of ACVR1R206H require the partner type I BMP receptors that are necessary for signaling
by wild-type ACVR1. These results demonstrate that the ACVR1-R206H and
G328R receptors have acquired a fundamentally altered signaling mechanism.
2.3: ACVR1-R206H and -G328R over-activate BMP signaling in the absence
of an intact ligand binding domain
Previous work by our lab showed that ACVR1-R206H can signal
independently of Bmp2/7 heterodimers, the only functional DV patterning ligand
in the zebrafish embryo (Little and Mullins 2009), suggesting that the mutant
receptor can signal independently of all BMP ligand (Shen, Little et al. 2009).
More recent studies have reported that ACVR1-R206H has an acquired
response to the TGFb family ligand, Activin A (Hatsell, Idone et al. 2015, Hino,
Horigome et al. 2017, Lees-Shepard, Yamamoto et al. 2018). This ligand
response has been implicated in inciting heterotopic ossification in patients with
FOP (Hino, Horigome et al. 2017, Alessi Wolken, Idone et al. 2018). Interestingly,
however, ACVR1-R206H can signal without its ligand binding domain in
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Drosophila and murine cell culture systems (Le and Wharton 2012, Haupt,
Deichsel et al. 2014, Hildebrand, Stange et al. 2017, Haupt, Xu et al. 2018).
To investigate in a vertebrate animal model if FOP-ACVR1 requires ligand
binding to signal, we used our zebrafish DV patterning assay to compare the
signaling function of normal mouse ACVR1 (Fig 2.1.1A) to mouse ACVR1 lacking
a 65 residue sequence containing the cysteine-rich ligand-binding motifs of the
extracellular domain (DACVR1) (Fig 2.1.1B) (Haupt, Deichsel et al. 2014). We
injected Acvr1 mRNA into 1-cell stage zebrafish embryos and tested if the
exogenously expressed ACVR1 protein correctly localized to the cell membrane
by immunostaining for the HA epitope tag present on these receptors. We found
that all of the ACVR1 protein variants, regardless of their signaling activity, were
expressed and localized to the cell membrane within the developing embryo (Fig
2.1.1A-F).
To determine if the ligand-binding domain mutant (D)ACVR1 receptors
were sufficient to pattern the zebrafish embryo, we knocked down endogenous
zebrafish acvr1l with morpholinos (MOs) and then expressed Acvr1 or DAcvr1
mRNAs. Knockdown of acvr1l generates the same severely dorsalized C5
phenotype as an acvr1l null mutation, consistent with loss of all BMP pathway
activity (Fig 2.1.1H and column 4 in I-K; Fig 2.1.2) (Bauer, Lele et al. 2001,
Mintzer, Lee et al. 2001, Little and Mullins 2009). At 12 to 14 hours post
fertilization (hpf) the C5 phenotype is characterized by an elongated body axis
and by an expansion of the normally dorsally-located somites around the
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circumference of the embryo. By 30 hpf these embryos lyse due to presumptive
pressure from the radialized somites. We evaluated rescue of BMP signaling
activity in these fish, assaying for less severe DV patterning phenotypes (Fig
2.1.1G) and quantifying the proportion of embryos in each phenotypic category.
Neither Acvr1 nor DAcvr1 mRNA greatly perturbed normal development in
the presence of endogenous acvr1l (Fig 2.1.1I columns 2 and 3, I’; Fig 2.1.2).
While Acvr1 (Fig 2.1.1I column 5, I’; Fig 2.1.2) rescued loss of endogenous
acvr1l, DAcvr1 did not (Fig 2.1.1I column 6, I’; Fig 2.1.2). By contrast, both Acvr1R206H and DAcvr1-R206H ventralized WT and acvr1l-KD zebrafish embryos (Fig
2.1.1J columns 2, 3, 5 and 6, J’; Fig 2.1.2). Likewise, both Acvr1-G328R and

DAcvr1-G328R ventralized WT and acvr1l-KD embryos (Fig 2.1.1K columns 2, 3,
5 and 6, K’; Fig 2.1.2). These results support that ACVR1-R206H and ACVR1G328R, unlike wild type ACVR1, exhibit ligand-independent signaling activity.
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Figure 2.1.1: ACVR1-R206H and -G328R over-activate BMP signaling in the
absence of an intact ligand binding domain. (A-F) ACVR1 domain schematics
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and immunostained shield stage (early gastrula) embryos expressing ACVR1
HA-tagged constructs. Nuclei (yellow), bcatenin (cyan), ACVR1-HA (magenta).
Scale bars = 40µm. (A) Uninjected (N=6) and Acvr1-injected (N=6) embryos. (B)
ΔAcvr1 injected embryos (N=5). (C) Acvr1-R206H injected embryos (N=9). (D)
ΔAcvr1-R206H injected embryos (N=4). (E) Acvr1-G328R injected embryos
(N=5). (F) ΔAcvr1-G328R injected embryos (N=5). (G) BMP signaling dosedependent 12-30 hpf zebrafish embryo phenotypes: severe dorsalization (C5-C4,
dark blue), mild dorsalization (C3-C1, light blue), wild-type development (WT,
violet), mild ventralization (V1-V3, light red), and severe ventralization (V4-V5,
dark red). (H) Representative phenotypes of wild-type embryos (evaluated at 12
and 30 hpf) or embryos injected with acvr1l MO (evaluated at 12 hpf, because
they do not survive to 30 hpf). (I-K) DV phenotypes of 12-30 hpf embryos
injected with Acvr1 or ΔAcvr1 mRNA alone or followed by acvr1l MO. Three
pooled experiments. (I) Acvr1 or ΔAcvr1 injected embryos. Columns: 1, N=221;
2, N=82; 3, N=95; 4, N=158; 5, N=83; 6, N=77. (I’) Representative 12 or 30 hpf
phenotypes. (J) Acvr1-R206H or ΔAcvr1-R206H injected embryos. Columns: 1,
N=221; 2, N=49; 3, N=63; 4, N=113; 5, N=45; 6, N=48. (J’) Representative 30
hpf phenotypes. (K) Acvr1-G328R or ΔAcvr1-G328R injected embryos. Columns:
1, N=221; 2, N=37; 3, N=108; 4, N=158; 5, N=40; 6, N=69. (K’) Representative
30 hpf phenotypes.
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Figure 2.1.2: ACVR1-R206H and -G328R over-activate BMP signaling in the
absence of an intact ligand binding domain. Representative 12-14 and 30 hpf
phenotypes of injected embryos.

2.4: ACVR1-R206H and -G328R over-activate pSmad1/5 signaling in the
absence of an intact ligand binding domain
During early embryonic development, a nuclear gradient of pSmad1/5
activity forms across the DV axis of the zebrafish embryo that specifies DV axial
cell fates (Tucker, Mintzer et al. 2008, Zinski, Bu et al. 2017, Zinski, Tuazon et al.
2019). This gradient persists throughout gastrulation and specifies DV fates. To
test how DAcvr1 mRNAs differentially phosphorylate Smad1/5 and generate this
signaling gradient, we knocked down endogenous Acvr1l, injected embryos with
mouse Acvr1 or mouse DAcvr1 mRNAs, and then immunostained early-gastrula
embryos (shield-65% epiboly stage) for pSmad1/5.
While wild-type embryos formed a gradient of pSmad1/5 expression that
peaks ventrally and decreases dorsally (Fig 2.2A) (Mucha, Hashiguchi et al.
2018), acvr1l-KD embryos lacked detectable pSmad1/5 signal (Fig 2.2A’). Acvr1
expression did not disturb the pSmad1/5 gradient in WT embryos and could
rescue pSmad1/5 in acvr1l-KD embryos (Fig 2.2B,B’). DAcvr1 also did not
perturb normal gradient formation in WT embryos, but could not rescue loss of
pSmad1/5 in acvr1l-KD embryos (Fig 2.2C,C’). Both Acvr1-R206H and DAcvr141

R206H restored pSmad1/5 signaling in acvr1l-KD embryos and greatly expanded
the signaling gradient dorsally (Fig 2.2D,D’,E,E’). Likewise Acvr1-G328R and

DAcvr1-G328R rescued and expanded the pSmad1/5 gradient even when
endogenous acvr1l was absent (Fig 2.2F,F’,G,G’). These results confirm that
ACVR1-R206H and ACVR1-G328R are able to over-activate Smad1/5
phosphorylation even in the absence of an intact ligand binding domain.

Figure 2.2: ACVR1-R206H and -G328R over-activate pSmad1/5 signaling in
the absence of an intact ligand binding domain. (A,A’-G,G’) Animal pole view
of relative pSmad1/5 intensities (using arbitrary units (AU)) within each nucleus
of the embryo in representative WT early-gastrula embryos (shield-65% epiboly
stage) with endogenous acvr1l present (A-G) or knocked down (A’-G’). Injected
mRNA is noted above for b-g and b’-g’. (A-C, A’-C’) Embryos are oriented with
ventral (V) side to the left and the dorsal (D) side to the right. (D-G, D’-G’) Dorsal
side of the embryo could not be identified due to loss of the shield structure with
ventralization. Scale bars = 200µm. (A, A’) Wild-type and acvr1l KD embryos,
respectively (N=19 and 17). (B, B’) Acvr1 injected embryos (N=6 and 8). (C, C’)
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ΔAcvr1 injected embryos (N=8 and 5). (D, D’) Acvr1-R206H injected embryos
(N=13 and 13). (E, E’) ΔAcvr1-R206H injected embryos (N=10 and 9). (F, F’)
Acvr1-G328R injected embryos (N=10 and 9). (G, G’) ΔAcvr1-G328R injected
embryos (N=5 and 10).

2.5: ACVR1-R206H and -G328R are responsive to Bmp7 ligand but
ΔACVR1-R206H is not
We next tested if FOP-ACVR1 with an intact ligand-binding domain
retained the ability to respond to ligand. Studies show that ACVR1 binds and
signals in response to Bmp7 (Allendorph, Isaacs et al. 2007, Heinecke, Seher et
al. 2009, Little and Mullins 2009, Yadin, Knaus et al. 2016). We injected human
WT- or FOP-ACVR1 mRNAs into bmp7-/- (bmp7sb1aub) zebrafish embryos that
also had acvr1l KD. We then determined whether Bmp7 ligand expression
enhanced signaling by these receptors.
Homozygous bmp7-/- embryos normally exhibit a severely dorsalized C5
phenotype (Fig 2.3.1A,B column 1; Fig 2.3.2) (Nguyen, Schmid et al. 1998, Dick,
Hild et al. 2000, Schmid, Furthauer et al. 2000). This dorsalization can be
rescued by injected bmp7 mRNA (Figs 2.3.1A,B column 2; Fig 2.3.2). In the
absence of acvr1l, bmp7 mRNA expression does not rescue bmp7-/- fish (Fig
2.3.1A, column 3; Fig 2.3.2). Conversely, in the absence of endogenous bmp7,
ACVR1 expression cannot rescue bmp7-/- fish (Fig 2.3.1B column 4, B’; Fig
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2.3.2), confirming that both of these components are required to pattern the
developing embryo. Co-injection of ACVR1 with bmp7 rescued embryos to less
dorsalized or wild-type phenotypes (Fig 2.3.1B column 5, B’; Fig 2.3.2). Similarly,
mouse Acvr1 rescued DV patterning with bmp7 mRNA, but could not pattern
embryos in the absence of bmp7 (Fig 2.3.3 columns 5 and 6). As expected
ΔAcvr1 could not rescue C5 dorsalized embryos regardless of the presence or
absence of bmp7 (Fig 2.3.3 columns 7 and 8), demonstrating that wild-type
ACVR1 requires an intact ligand binding domain to signal with BMP ligand.
Both ACVR1-R206H and Acvr1-R206H rescued bmp7-/-, acvr1l-KD fish,
primarily to mildly ventralized phenotypes (Fig 2.3.1C column 4, C’; Fig 2.3.2,
2.3.3 column 9). This rescue was enhanced to severe ventralization by the
addition of bmp7 ligand (Fig 2.3.1C column 5, C’, Figs 2.3.2, 2.3.3 column 10). Of
note, ΔAcvr1-R206H did not cause enhanced ventralization in the presence of
bmp7, supporting that loss of the ligand binding domain prevents ligand response
(Fig 2.3.3, compare column 12 to 11). ACVR1-G328R rescued bmp7-/- embryos
to less severe dorsalization phenotypes (Fig 2.3.1D column 4, D’, Fig 2.3.2) and
induced further ventralization in response to bmp7 ligand (Fig 2.3.1D column 5,
D’; Fig 2.3.2). These data show that ACVR1-R206H and ACVR1-G328R are
responsive to BMP ligand, and together with the data in Figures 2.1 and 2.2,
show that these FOP-ACVR1 mutant receptors have both ligand-independent
and ligand-responsive activity.

44

45

Figure 2.3.1: ACVR1-R206H and -G328R are responsive to BMP7 ligand. (A)
Representative 12-30 hpf DV phenotypes of bmp7-/- embryos not injected (12
hpf), injected with bmp7 mRNA (12 and 30 hpf), or bmp7 mRNA with acvr1l KD
(12-14 hpf). (B-D) 12-30 hpf DV phenotypes of bmp7-/- embryos with acvr1l KD
that were injected with an ACVR1 mRNA alone or in combination with bmp7
mRNA. (B) ACVR1 injected embryos. Three pooled experiments. Columns: 1,
N=240; 2, N=150; 3, N=143; 4, N=101; 5, N=120. (B’) Representative 12 and 30
hpf phenotypes. (C) ACVR1-R206H injected embryos. Two pooled experiments.
Columns: 1, N=177; 2, N=78; 3 N=132; 4, N=100; 5, N=86. (C’) Representative
12 and 30 hpf phenotypes. (D) ACVR1-G328R injected embryos. Two pooled
experiments. Columns: 1, N=52; 2, N=46; 3, N=55; 4, N=56; 5, N=82. (D’)
Representative 12 and 30 hpf phenotypes.
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Figure 2.3.2: ACVR1-R206H is responsive to BMP7 ligand but DAcvr1R206H is not. Representative 12-14 and 30 hpf phenotypes of injected embryos.
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Figure 2.3.3: ACVR1-R206H but not DACVR1-R206H is responsive to BMP7
ligand. DV phenotypes at 12-30 hpf of injected bmp7-/- embryos with acvr1l KD
injected with mAcvr1, DAcvr1, Acvr1-R206H, or DAcvr1-R206H mRNA alone or
followed by bmp7 mRNA injection. Three pooled experiments. Columns: 1,
N=383; 2, N=109; 3, N=143; 4, N=134; 5, N=168; 6, N=158; 7, N=95; 8, N=84; 9,
N=72; 10, N=94; 11, N=55; 12, N=100.

2.6: ACVR1-R206H signals in the absence of all other Type I BMP receptors
BMP ligand is required for the association of ACVR1 with BMPR1 in the
zebrafish (Little and Mullins 2009). Therefore, the ability of FOP-ACVR1 to signal
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independently of ligand suggests the possibility of signaling in the absence of
receptor complex partners as well. In the developing zebrafish, both the type I
BMP receptors ACVR1 and BMPR1 are required for signaling and to pattern the
embryo (Mintzer, Lee et al. 2001, Little and Mullins 2009). Previous studies
showed that ACVR1-R206H retained the ability to over-activate BMP signaling
when either BMPR1A or BMPR1B was knocked down in cell culture (Hino, Ikeya
et al. 2015). However, given that these two genes have largely redundant activity
(Wine-Lee, Ahn et al. 2004, Yoon, Ovchinnikov et al. 2005), one copy of BMPR1
(A or B) may be sufficient to allow ACVR1-R206H to signal.
To test if ACVR1-R206H is able to signal in the absence of all other type I
BMP receptors, we intercrossed bmpr1aa+/-, bmpr1ab-/- zebrafish and injected
their embryos with MOs against bmpr1ba, bmpr1bb and acvr1l to generate fish
deficient in all type I BMP receptors (designated as Type I KD henceforth) (Fig
2.4.1A). We then injected these Type I KD fish with human ACVR1-R206H
mRNA. Embryos were collected at an early gastrula stage for pSmad1/5
immunostaining or at 12 to 30 hpf for phenotyping, analyzed blindly, then
genotyped for the bmpr1aa mutation. Using immunostaining, we confirmed that
Flag tagged ACVR1-R206H is expressed and localized to the cell membrane in
Bmpr1a+/- fish (Fig 2.4.1B).
Both bmpr1aa+/+,ab-/- (bmpr1a+/+) and bmpr1aa+/+,ab-/- (bmpr1a+/-)
embryos developed normally (Fig 2.4.1C, column 1; Fig 2.4.2), but embryos null
for both bmpr1aa and bmpr1ab (bmpr1a-/-) were severely dorsalized to a C4
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phenotype (Fig 2.4.1C column 7; Fig 2.4.2). bmpr1b KD does not affect DV
patterning of bmpr1a+/+ or +/- embryos (Fig 2.4.1C column 2; Fig 2.4.2),
demonstrating that bmpr1aa with acvr1l is sufficient to pattern the zebrafish
embryo. However, bmpr1b KD further dorsalized bmpr1a-/- embryos to a C5
phenotype (Fig 2.4.1C column 8; Fig 2.4.2). Embryos were all severely
dorsalized to a C5 phenotype by KD of bmpr1b and acvr1l (Fig 2.4.1C column 3;
Fig 2.4.2) and Type I KD embryos were also dorsalized to a C5 phenotype (Fig
2.4.1C Column 9; Fig 2.4.2). ACVR1-R206H was able to ventralize Type I KD
embryos, demonstrating that it does not require any other type I BMP receptor to
pattern the embryo (Fig 2.4.1C column 12; Fig 2.4.2). Similarly, ACVR1-G328R
was able to ventralize Type I KD embryos, demonstrating in shares the ability to
signal without any other type I BMP receptors (Fig 2.4.3).
We observed a wild-type pSmad1/5 gradient in bmpr1a+/- embryos (Fig
2.4.1D), while pSmad1/5 signal was absent in Type I KD embryos (Fig 2.4.1F).
ACVR1-R206H rescued signaling and expanded the pSmad1/5 signaling
gradient dorsally in both bmpr1a+/- embryos (Fig 2.4.1E) and Type I KD embryos
(Fig 2.4.1G). These data demonstrate that FOP-ACVR1 does not require any
other type I BMP receptors for signaling and that this mutant receptor does not
need to be part of, or even require the presence of wild-type ACVR1-BMPR1
signaling complexes.
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Figure 2.4.1: ACVR1-R206H signals in the absence of all other type I BMP
receptors. (A) Experimental workflow. bmpr1aa+/-,ab-/- fish were crossed with
each other to generate bmpr1a+/- (bmpr1aa+/+,ab-/-), bmpr1a+/- (bmpr1aa+/,ab-/-) and bmpr1a-/- (bmpr1aa+/-,ab-/-) embryos. One-cell stage eggs were
injected with bmpr1ba, bmpr1bb, and acvr1l morpholinos to knockdown these
endogenous BMP receptors and were additionally injected with ACVR1-R206H
mRNA. Early gastrula (shield-65% epiboly) stage embryos were collected and
fixed for immunostaining. At 12 to 30 hpf the remaining embryos were scored for
DV patterning phenotypes. Following immunostaining and imaging, or
phenotyping, embryos were collected and individually genotyped. (B)
Representative immunostained embryo for ACVR1-Flag (magenta), beta-Catenin
(marking the cell membrane cyan), and nuclei (yellow) (N=5). (C) Injected
embryo phenotypes at 12 to 30 hpf. Three pooled experiments. Columns: 1,
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N=104; 2, N=41; 3, N=69; 4, N=69; 5, N=78; 6, N=70; 7, N=36; 8, N=19; 9, N=25;
10, N=29; 11, N=23; 12, N=22. (D-G) Animal pole view of relative pSmad1/5
intensities (AU) within each nucleus in representative WT early-gastrula
embryos. (D and F) Embryos are oriented with the ventral (V) side to the left and
the dorsal (D) side to the right. (E and G) Dorsal side of the embryo could not be
identified due to loss of the shield structure with ventralization. (D) bmpr1a+/embryo (N=5). (E) bmpr1a-/- embryo with acvr1l and bmpr1b KD (Type I KD
embryo) (N=8). (F) bmpr1a+/- embryo injected with ACVR1-R206H mRNA (N=5).
(G) Type I KD embryo injected with ACVR1-R206H mRNA (N=3).
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Figure 2.4.2: ACVR1-R206H signals in the absence of all other I BMP
receptors. Representative 12 and 30 hpf phenotypes of injected embryos.
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Figure 2.4.3: ACVR1-G328R signals in the absence of all other type I BMP
receptors. Injected embryo phenotypes at 12 to 30 hpf. Two pooled
experiments. Columns: 1, N=24; 2, N=76; 3, N=101; 4, N=66; 5, N=72; 6, N=59;
7, N=36; 8, N=28; 9, N=32; 10, N=20; 11, N=30; 12, N=13.

2.7: DACVR1-R206H signals in the absence of all other type I BMP
receptors
To test if FOP-ACVR1 ligand-independent signaling requires Bmpr1 or
endogenous Acvr1l, we injected Type I KD embryos with mouse Acvr1-R206H or
mouse DAcvr1-R206H and evaluated DV patterning phenotypes at 30 hpf and
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dorsal marker expression in 5- to 9-somite stage embryos. Interestingly, like
Acvr1-R206H, DAcvr1-R206H also ventralized Type I KD embryos (Fig 2.5.1A,B
column 8; Fig 2.5.2), indicating that ligand-independent ACVR1-R206H signaling
also does not require other type I BMP receptors to pattern the zebrafish embryo.
We then evaluated expression of two dorsal markers, pax2.1 and krox20,
by wholemount in situ hybridization. In normal 5 to 9 somite stage embryos,
pax2.1 is expressed in the midbrain-hindbrain (MHB) boundary (Fig 2.5.1C, white
arrowhead at anterior) and krox20 is expressed in rhombomeres 3 and 5 (Fig
2.5.1C, black arrowheads) (Krauss, Johansen et al. 1991, Strahle, Blader et al.
1993, Thisse, Pflumio et al. 2001, Hashiguchi and Mullins 2013). In bmpr1a-/embryos, which develop to a C4 dorsalized phenotype, the MHB and
rhombomere expression of pax2.1 and krox20, respectively, was expanded
laterally (Fig 2.5.1D). In Type I KD embryos, which display a C5 dorsalized
phenotype, krox20 became radially expressed in rhombomere 5, and the MHB
and rhombomere 3 were expanded laterally (Fig 2.5.1E). Acvr1-R206H mRNA
injection rescued Type I KD embryos to a ventralized phenotype, characterized
by dorsally-restricted neural expression of pax2.1 and krox20 compared to Type I
KD embryos (Fig 2.5.1F). Injection of Type I KD embryos with DAcvr1-R206H
mRNA, which lacks critical regions of the ligand binding domain, similarly
restricted expression of pax2.1 and krox20 to dorsal regions (Fig 2.5.1G). These
data demonstrate that ligand-independent signaling by ACVR1-R206H does not
require other type I BMP receptors.
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Figure 2.5.1: DACVR1-R206H signals in the absence of all other type I BMP
receptors. (A-B) Injected bmpr1a+/- or -/- 12 to 30 hpf embryo phenotypes with
bmpr1b KD, acvr1 KD with or without Acvr1-R206H or DAcvr1-R206H mRNA.
Two pooled experiments. (A) Acvr1-R206H injected embryos. Columns: 1,
N=150; 2, N=80; 3, N=98; 4, N=89; 5, N=76; 6, N=36; 7, N=31; 8, N=30. (B)

DAcvr1-R206H injected embryos. Columns: 1, N=150; 2, N=80; 3, N=92; 4,
N=127; 5, N=76; 6, N=36; 7, N=26; 8, N=37. (C-I) Representative dorsal view of
pax2.1 (white arrowheads: anteriorly in the midbrain-hindbrain boundary and
posteriorly in the pronephric mesoderm), krox20 (black arrowheads;
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rhombomeres 3 and 5), and myod (black arrow; paraxial mesoderm) expression
in 5-9 somite stage bmpr1a+/- or -/- embryos with bmpr1b KD, acvr1 KD with or
without Acvr1-R206H or DAcvr1-R206H. Two experiments. Embryos are oriented
with the anterior (A) side left and the posterior (P) side right. (C) bmpr1a+/embryo. (D) bmpr1a-/- embryo. (E) bmpr1a-/- embryo with acvr1l and bmpr1b KD
(Type I KD embryo). (F) Type I KD embryo injected with Acvr1 mRNA. (G) Type I
KD embryo injected with DAcvr1-R206H mRNA.
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Figure 2.5.2: DACVR1-R206H signals in the absence of all other type I BMP
receptors. Representative 12 and 30 hpf phenotypes of injected embryos

2.8: ACVR1-R206H responds to ligand in the absence of all other type I
BMP receptors
Since ligand facilitates association of Acvr1 and Bmpr1 in the developing
zebrafish (Little and Mullins 2009), we next examined if FOP-ACVR1 requires
other type I BMP receptors for its enhanced ventralizing activity in response to
ligand. We expressed human ACVR1-R206H in Type I KD embryos that were
either deficient in BMP (by overexpressing the BMP ligand-binding inhibitor
Chordin (Chd)) or overexpressed Bmp7. Embryos were evaluated for DV
patterning and dorsal marker gene expression.
chd overexpression dorsalized embryos in both the presence and absence
of bmpr1a (Fig 2.6.1A columns 1 and 9; Fig 2.6.2). While bmp7 overexpression
ventralized embryos in the presence of bmpr1a (Fig 2.6.1A column 3; Fig 2.6.2),
bmp7 had no effect on patterning in bmpr1 deficient or Type I KD embryos, as
expected (Fig 2.6.1A column 11 and 13; Fig 2.6.2). As described in Figure 4C,
ACVR1-R206H ventralized embryos even in the absence of all other type I BMP
receptors (Fig 2.6.1A, column 15; Fig 2.6.2). Comparatively, overexpression of
chd inhibited ventralization by ACVR1-R206H with or without Bmpr1 (Fig 2.6.1A
columns 6 and 14, compare to columns 7 and 15; Fig 2.6.2), consistent with
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reduced BMP pathway activity. Overexpression of bmp7 enhanced ventralization
by ACVR1-R206H with or without bmpr1, consistent with increased signaling (Fig
2.6.1A, compare columns 8 and 16, to columns 7 and 15; Fig 2.6.2).
We next evaluated 5-9 somite stage embryos for pax2.1 and krox20
expression using in situ hybridization. Compared to bmpr1a+/+ and +/- embryos
(Fig 2.6.1B, as in Fig. 2.5.1C), bmpr1-/- embryos have expanded neural
expression of pax2.1 and krox20 (Fig 2.6.1C, as in Fig, 2.5.1D) and Type I KD
embryos have radialized expression of krox 20 (Fig 2.6.1D, as in Fig. 2.5.1E).
Type I KD embryos co-injected with ACVR1-R206H and chd mRNA had dorsallyrestricted expression of pax2.1 and krox20 compared to Type I KD embryos,
although not as restricted as bmpr1a+/- embryos, consistent with moderately
dorsalized phenotypes (Fig 2.6.1E). Type I KD embryos injected with ACVR1R206H or co-injected with ACVR1-R206H and bmp7, expressed pax2.1 and
krox20 in patterns similar to, or more dorsally-restricted than bmpr1a+/- embryos,
consistent with rescue to wild-type or ventralized phenotypes (Fig 2.6.1F and G).
These results demonstrate that ACVR1-R206H is able to respond to ligand in the
absence of all other type I BMP receptors.
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Figure 2.6.1: ACVR1-R206H responds to ligand in the absence of all other
type I BMP receptors. (A) 12-30 hpf phenotypes of bmpr1a+/- or -/- embryos
with bmpr1b KD and acvr1l KD with or without ACVR1-R206H, with or without
chordin mRNA or bmp7 mRNA. Four pooled experiments and two experiments
with controls only. Columns: 1, N=172; 2, N=160; 3, N=106; 4, N=135; 5, N=104;
6, N=121; 7, N=169; 8, N=117; 9, N=32; 10, N=91; 11, N=16; 12, N=57; 13,
N=29; 14, N=28; 15, N=49; 16, N=49. (B-G) Representative dorsal view of
pax2.1, krox20, and myod expression in 5-9 somite stage bmpr1a+/- or -/embryos with bmpr1b KD, acvr1 KD, with or without ACVR1-R206H, and with or
without chd or bmp7 mRNA. Three experiments. Embryos are oriented with the
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anterior (A) side left and the posterior (P) side right. (B) bmpr1a +/- embryo. (C)
bmpr1a-/- embryo. (D) bmpr1a-/- embryo with acvr1l and bmpr1b KD (Type I KD
embryo). (E) Type I KD embryo injected with ACVR1-R206H and chd mRNA. (F)
Type I KD embryo injected with ACVR1-R206H mRNA. (G) Type I KD embryo
injected with ACVR1-R206H and bmp7 mRNA
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Figure 2.6.2: ACVR1-R206H responds to ligand in the absence of all other
type I BMP receptors. Representative 12 and 30 hpf phenotypes of injected
embryos.

2.9: Discussion
Using an in vivo zebrafish model, a highly informative and sensitive
vertebrate system for BMP signaling activity during DV patterning, we
investigated the signaling mechanism of the ACVR1 type I BMP receptor and the
effects of ACVR1 activating mutations that cause a rare genetic disorder of
ectopic bone formation. We show that while wild-type ACVR1 requires its ligand
binding domain for signaling, the FOP-ACVR1 mutants, ACVR1-R206H and
ACVR1-G328R, do not require an intact ligand binding domain to over-activate
pSmad1/5 signaling. However, these mutant receptors do retain the ability to
respond to BMP ligand when their ligand binding domain is intact. We further
show for the first time that Bmpr1, while required for signaling by WT-Acvr1l, is
dispensable for both ligand-independent and ligand-responsive signaling by
mutant FOP-ACVR1. Our data suggest that the causative mutations of FOP
allow the mutant receptor to bypass normal ligand-receptor complex assembly.
This aberrant signaling highlights the importance of ligand-receptor complex
assembly to facilitate and direct normal signaling by ACVR1. Elucidation of FOPACVR1 signaling mechanisms not only provides insight into therapeutic targets
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for treating FOP, but also gives us unique insight into how BMP signaling is
regulated.
Our study demonstrates that ACVR1-R206H and ACVR1-G328R do not
require direct ligand binding to signal. This does not preclude the possibility that
other components of an FOP-ACVR1 signaling complex play a role in ligand
binding. However, given that these mutant receptors can signal in the absence of
the endogenous zebrafish patterning ligand Bmp2/7 (Shen, Little et al. 2009),
and ligand-binding deficient ACVR1 does not respond to Bmp7 ligand, we
conclude that FOP-ACVR1 is able to signal independently of BMP ligands
regardless of binding by other receptors in the signaling complex. The inability of
ligand-binding deficient ACVR1 to respond to Bmp7 in our study and Activin A in
other studies (Hildebrand, Stange et al. 2017) further suggests it does not have
the ability to bind ligand, and therefore does not need ligand to signal.
Normally, assembly of the BMP-pSmad1/5 signaling receptor complex is
mediated by ligand binding. In zebrafish, ACVR1 and its type I BMP receptor
partners will not associate with each other and signal in the absence of
appropriate ligands (Little and Mullins 2009). Therefore, the ability of ACVR1R206H and -G328R to signal in the absence of an intact ligand-binding domain
was unexpected and suggests an acquired ability to signal in the absence of
normal complex formation. Indeed, in this study we also determined that ACVR1R206H does not require any other type I BMP receptors for its signaling activity.
We note that in our experimental system, maternal bmpr1aa mRNA remains
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present in our bmpr1aa-/-,ab-/- mutants; however, the inability of bmp7
overexpression to rescue the C4 dorsalized phenotype indicates that this
maternal bmpr1aa has little or no effect on DV patterning.
The ability of ACVR1-R206H and -G328R to signal in the absence of a
ligand-binding domain and, in the case of ACVR1-R206H, the normal ACVR1
type I receptor partners, suggests that the mutations that occur in FOP allow the
mutant receptor to bypass complex assembly. As a result, the mutant receptor is
freed from regulation by ligand and receptor partner availability. In the context of
the developing zebrafish, these mutations decouple the activity of ACVR1 from
its morphogen signal.
Previous studies have suggested that the FOP mutations weaken binding
by the Type I receptor inhibitor FKBP12, allowing for constitutive or ‘leaky’
signaling (Chen, Liu et al. 1997, Huse, Chen et al. 1999, Groppe, Wu et al.
2011). However, more recent evidence suggests that this loss of FKBP12
inhibition does not fully account for the level of increased activity displayed by the
FOP mutant receptors (Machiya, Tsukamoto et al. 2018). ACVR1-R206H has
been shown to still require type II BMP receptors and GS domain activation to
signal (Le and Wharton 2012, Bagarova, Vonner et al. 2013, Hino, Ikeya et al.
2015). In the absence of complex assembly with other type I receptors, GS
domain activation of FOP-ACVR1 may occur by stochastic association with free
type II BMP receptors. These data highlight that even more remains to be
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elucidated about the mechanism by which BMP receptor components assemble
and coordinately regulate signaling.
The ligand responsive activity that we observed by ACVR1-R206H and
-G328R may reflect stabilization of signaling activity by ligand-facilitated receptor
complex assembly. Studies suggest that not only is ligand critical for type I
receptor complex assembly, it also mediates which receptors assemble together
through differential ligand-receptor affinity (Allendorph, Isaacs et al. 2007,
Heinecke, Seher et al. 2009, Little and Mullins 2009, Yadin, Knaus et al. 2016,
Antebi, Linton et al. 2017). Recent studies have shown that FOP-ACVR1 has
acquired the ability to signal in response to the TGFb family ligand Activin A,
which normally binds ACVR1b and signals through pSmad2/3 (Hatsell, Idone et
al. 2015, Hino, Ikeya et al. 2015, Lees-Shepard, Yamamoto et al. 2018). By
RNAseq and wholemount in situ hybridization, low levels of activin A expression
were detectable in the prechordal plate during late gastrulation (75% epiboly)
(Thisse, Heyer et al. 2004, White, Collins et al. 2017), a stage later than our
analysis of pSmad1/5 at early gastrulation (shield to 65% epiboly) (Figs 2.2,
2.4.1D-G). However, another report detected low activin A expression during
early gastrulation by RT-PCR (Hashiguchi, Shinya et al. 2008), thus we cannot
exclude Activin A as a factor in FOP-ACVR1 signaling in our system. The ability
to signal with a greater repertoire of ligands, or even with no ligand, may allow
FOP-ACVR1 to signal with a greater repertoire of type I receptor partners.
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Our results show that FOP-ACVR1 can respond to ligand without its
normal type I BMP receptor partner, Bmpr1. In the absence of Bmpr1, ACVR1R206H may homodimerize with itself to signal. BMPR1, although not ACVR1,
has been shown to form inert pre-formed homodimer complexes that are poised
to respond to ligand (Marom, Heining et al. 2011). ACVR1, however, normally
binds ligand poorly on its own, indicating that this type I receptor may not easily
associate or form stable complexes with ligand in the absence of other receptor
partners (Heinecke, Seher et al. 2009). In our study, the type II BMP receptors
are present in the zebrafish embryo and may be sufficient to form a working
signaling complex with FOP-ACVR1 that can still respond to ligand.
Alternatively, FOP-ACVR1 may have acquired the ability to associate with
other type I TGFb receptors. Recent studies have shown that TGFbR1 can
associate with ACVR1 and initiate pSmad1/5 signaling (Ramachandran, Vizan et
al. 2018). ACVR1b, the Nodal/Activin receptor, is also present in the zebrafish
embryo. Notably, ACVR1b uses the same type II receptors, ACVR2a and
ACVR2b, as ACVR1 to signal, although these complexes signal through
pSmad2/3 rather than pSmad1/5. Inert and inhibitory receptor complexes have
also been shown to regulate signaling by TGFbR1 (Wang, Chun et al. 2019). A
possibility is that WT-ACVR1 may associate but not signal in complex with
TGFbR1 and ACVR1b receptors, and introduction of the FOP mutations allow
these inert complexes to signal. Further investigation into the receptor complexes
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formed with ACVR1-R206H may give us insight into inert or inhibitory complexes
that form and regulate BMP signaling generally and ACVR1 signaling specifically.
The pathological significance of the signaling modalities elucidated in this
study remain to be further investigated. One possibility is that they represent two
observed forms of HO initiation in FOP patients: spontaneous and injury-induced.
Ligand-independent basal activity of FOP-ACVR1 may lead to increasing levels
of signaling within tissues and the initiation of spontaneous HO when a threshold
is reached with no obvious inciting factor (Shore and Kaplan 2010). Ligandresponsive hyperactivity may account for injury-induced HO, in which cascades
of signaling in response to injury-induced ligands, including Activin A (Hatsell,
Idone et al. 2015, Hino, Ikeya et al. 2015, Lees-Shepard, Yamamoto et al. 2018),
contribute to increased activity by FOP-ACVR1. Studies in adult zebrafish have
reported that while constitutively active ACVR1 causes skeletal malformations,
ligand overexpression does not induce heterotopic ossification, suggesting that
key additional factors may be at play in addition to the BMP ligands and
receptors present (LaBonty, Pray et al. 2017, LaBonty, Pray et al. 2018).
Research to identify FOP treatment strategies has examined multiple drug
targets in ACVR1 signaling including ligand binding and ACVR1 kinase activity
(Cappato, Giacopelli et al. 2018). Our data suggest that targeting the kinase
activity of FOP-ACVR1 itself appears to be a highly promising candidate for
treatment.
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CHAPTER 3: The GS and kinase domains facilitate overactive
signaling by Fibrodysplasia Ossificans Progressiva mutant
ACVR1
3.1: Summary
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic condition
characterized by developmental skeletal malformations and progressive
heterotopic ossification (HO). All cases of FOP are caused by mutations to the
type I bone morphogenetic protein (BMP) receptor ACVR1 and over-activate
BMP pathway signaling through phospho-Smad1/5 (pSmad1/5). Activation of the
wild-type ACVR1 kinase requires phosphorylation of the GS domain by type II
BMP receptors. Previous studies have shown that both type II receptors and
presumptive phosphorylation of the GS domain are required for over-active
signaling by the FOP mutant ACVR1-R206H. Structural modeling of ACVR1R206H supports that the mutation alters the conformation of the GS domain, but
it is unclear how this leads to overactive signaling by ACVR1. Here we show that
the FOP mutant receptors ACVR1-R206H and -G328R have a reduced
requirement for GS domain phosphorylation sites compared to wild-type ACVR1.
Further, ligand independent and ligand dependent signaling through the FOP
receptors have differential GS domain phosphorylation site requirements, and do
not require other type I BMP receptors under either circumstance. FOP-ACVR1
remains sensitive to ATP competitive binding inhibitors like ACVR1. Interestingly,
although the zebrafish paralog of ACVR1-R206H, Acvr1-R203H, does not have
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increased signaling activity, substitution of the zebrafish kinase domain with the
human kinase domain is sufficient to facilitate overactive signaling. These results
demonstrate that interaction between the GS domain and kinase domain is
important for the FOP mutations to convey increased signaling. Together these
data reflect the complex effect of the FOP mutations on regulating the activation
threshold of ACVR1.
3.2: Introduction
Fibrodysplasia ossificans progressiva (FOP) is a rare human disease
characterized by both skeletal malformations and abberant formation of bone
within soft connective tissues, or heterotopic ossification (HO) (Connor and
Evans 1982, Cohen, Hahn et al. 1993, Kaplan, Xu et al. 2009). All cases of FOP
are caused by activating mutations in the type I TGFb/BMP receptor, ACVR1
(Shore, Xu et al. 2006, Fukuda, Kohda et al. 2009, Shen, Little et al. 2009, van
Dinther, Visser et al. 2010). The most common causative mutation of FOP is a
single amino acid change, R206H, within the GS domain of ACVR1. Other
mutations that cause FOP also occur within the GS domain or in the kinase
domain of this receptor (Kaplan, Xu et al. 2009). While these variant mutations
have been found to over-activate the BMP signaling pathway through pSmad1/5
(Fukuda, Kohda et al. 2009, Shen, Little et al. 2009, Haupt, Xu et al. 2018,
Mucha, Hashiguchi et al. 2018), the mechanism by which these mutations alter
activity of ACVR1 itself requires further elucidation.
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Wild-type ACVR1 signals in a receptor heterotetramer with one other type
I BMP receptor, BMPR1, and two type II BMP receptors (Little and Mullins 2009,
Ramel and Hill 2012, Zinski, Tajer et al. 2018). This receptor heterotetramer
assembles around the BMP ligand (Greenwald, Groppe et al. 2003, Allendorph,
Vale et al. 2006, Allendorph, Isaacs et al. 2007, Groppe, Hinck et al. 2008, Little
and Mullins 2009). Proximity of the receptors within this heterotetramer allows
the constitutively active kinase activity of the type II BMP receptors to
phosphorylate the type I BMP receptors at their GS domain (Wrana, Attisano et
al. 1994, Attisano, Wrana et al. 1996, Shi and Massague 2003, Schmierer and
Hill 2007). The GS domain is highly conserved between the multiple type I TGFb
receptors and across vertebrate species. Within this domain are several serines
and threonines within a Glycine (G)-Serine (S) motif for which the domain is
named. GS domain phosphorylation activates the kinase of the type I BMP
receptor, which allows it to phosphorylate Smad1/5 (Liu, Hata et al. 1996, Feng
and Derynck 2005, Chaikuad, Alfano et al. 2012).
Evaluation of tertiary structures revealed that most of the amino acids
altered by ACVR1-FOP mutations occur on the same face of the receptor
(Chapter 1, Fig 1.3) (Groppe, Shore et al. 2007, Kaplan, Xu et al. 2009),
suggesting that these mutations may over-activate signaling through a similar
mechanism. Previous results by our lab showed that the FOP-ACVR1 could
signal without its ligand binding domain or other type I BMP receptors,
demonstrating that the BMP receptor complex requirements of this mutant
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receptor is fundamentally altered (Chapter 2) (Shen, Little et al. 2009, Mucha,
Hashiguchi et al. 2018). However, loss of BMPR2 and ACVR2a or the
Serine/Threonine residues within the GS domain both abrogate signaling by
ACVR1-R206H (Le and Wharton 2012, Bagarova, Vonner et al. 2013, Hino,
Ikeya et al. 2015), suggesting that phosphorylation of the GS domain is still
required for FOP-ACVR1 to signal.
The zebrafish embryo has been used extensively as a model to assay for
BMP signaling by FOP-ACVR1 (Shen, Little et al. 2009, Mucha, Hashiguchi et al.
2018). In a biological mechanism conserved throughout the animal kingdom, the
zebrafish establishes its dorso-ventral (DV) embryonic axis with a gradient of
BMP signaling activity (Mintzer, Lee et al. 2001, Tucker, Mintzer et al. 2008,
Zinski, Tajer et al. 2018, Zinski, Tuazon et al. 2019). Loss of BMP signaling
activity results in expansion of dorsal cell fates at the expense of ventral fates, or
dorsalization, while overactivation of BMP signaling leads to an opposite
ventralization. The use of zebrafish DV patterning as a high throughput screen
for changes in BMP activity led to the discovery of the type I BMP receptor
inhibitor, Dorsomorphin (Yu, Hong et al. 2008). In addition, zebrafish DV
patterning was the first in vivo model to show that ACVR1-R206H over-activates
signaling through pSmad1/5 (Shen, Little et al. 2009, Mucha, Hashiguchi et al.
2018). Interestingly, however, we found that Acvr1l-R203H, the zebrafish paralog
of ACVR1-R206H, does not overactivate signaling. Determining which
components of the ACVR1-R206H receptor allow for overactive signaling will
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provide insight into how this mutation leads to disease and pave the way for an
endogenous model of FOP in zebrafish, as well as provide important new insight
into the mechanisms that normally regulate BMP receptor activity.
Here we use an in vivo zebrafish DV patterning model to further evaluate
the importance of the GS and kinase domains for overactive signaling by FOPACVR1. We show that ACVR1-R206H and -G328R have a decreased GS
domain phosphorylation site residue requirement compared to ACVR1. In
addition, ACVR1-R206H and -G328R have stricter GS phosphorylation site
requirements for ligand-independent signaling compared to ligand-dependent
signaling. Regardless, FOP-ACVR1 GS domain mutants still do not require any
other type I BMP receptors to signal. As expected, kinase activity is critical for
ACVR1-R206H and -G328R to initiate BMP signaling. Further, we found that the
human kinase domain was sufficient to make the normally non overactive
zebrafish Acvr1l-R203H become over-activating, suggesting that interaction
between the GS and kinase domains is critical for the FOP mutations to cause
disease.
3.3: GS mutant ACVR1-R206H, but not -G328R, can signal independently of
Bmp7
Previously we determined that FOP-ACVR1 can signal independently of
both ligand and other type I BMP receptors, suggesting that this receptor can
signal independently of complex assembly (Chapter 2). However, previous
studies have found that the type II BMP receptors are important for signaling by
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FOP-ACVR1 (Bagarova, Vonner et al. 2013, Hino, Ikeya et al. 2015). Type II
BMP receptors activate wildtype ACVR1 kinase activity via GS domain
phosphorylation. Within the GS domain are four serine/threonine residues, T189,
S190, S192 and S194 (Fig 3.1), which are phosphorylated by type II BMP
receptors and have been shown to be collectively important for signaling by
ACVR1-R296H (Attisano, Wrana et al. 1996, Le and Wharton 2012). However,
given the evidence that the R206H mutation may act as a phosphomimetic to
decrease the activation threshold of ACVR1-R206H, FOP-ACVR1 may have an
altered requirement for GS domain activation.
To test the role of ACVR1 GS domain activation by type II BMP receptors,
we mutated threonine and serine residues of the ACVR1 GS domain to
structurally similar, but non-phosphorylatable valine and alanine residues,
respectively. We then evaluated the signaling activity of these GS mutant
receptors using zebrafish DV patterning as an assay for BMP signaling activity
(see Chapter 2, Fig 2.1.1G). We first tested the signaling activity of ACVR1
receptors in which the GS domain was not mutated (TSSS) or single residues
were mutated; T189V (VSSS), S190A (TASS), or S192A (TSAS) (Fig 3.1). Loss
of single serine or threonine residues in the conserved GS domain of TGFbR1
did not prevent signaling, suggesting that 3 serine/threonine residues within this
domain is sufficient for signaling (Franzen 1995, Weiser 1995). We tested the
ability of our GS domain mutant receptor mRNAs to ventralize wild-type embryos
and rescue the C5 dorsalized phenotype that occurs with Acvr1 depletion or
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genetic removal of Bmp7 ligand by using wild-type embryos with acvr1l KD,
bmp7-/- embryos with acvr1l KD, and bmp7-/- embryos with acvr1l KD and bmp7
mRNA overexpression.
Both wild-type ACVR1 and FOP-ACVR1 can compensate for loss of
Acvr1l during DV patterning. Loss of either acvr1l or bmp7 severely dorsalizes
zebrafish embryos because both of these BMP signaling components are
normally required for zebrafish DV patterning (Fig 3.2A, columns 5 and 9).
Misexpression of ACVR1 with an intact GS domain (TSSS) had little effect on DV
patterning in WT embryos (Fig 3.2A column 2), but can rescue loss of
endogenous acvr1l (Fig 3.2A column 6). ACVR1-TSSS cannot rescue DV
patterning in the absence of Bmp7 ligand (Fig 3.2A column 10), but when ligand
is reintroduced it can (Fig 3.2A column 15). ACVR1-TSSS-R206H over-activates
signaling and ventralizes zebrafish regardless of the presence or absence of
Acvr1l or Bmp7 (Fig 3.2A columns 3, 7, 11 and 16). Likewise, ACVR1-G328R
TSSS activates signaling regardless of the presence or absence of Acvr1l or
Bmp7 (Fig 3.2A columns 4, 8, 12 and 17). However, as previously observed,
ACVR1-G328R is much more responsive to Bmp7 than ACVR1-R206H (Fig 3.2A
columns 12 and 17 compared to columns 11 and 16).
Loss of T189 did not prevent wild-type ACVR1 or FOP-ACVR1 from
patterning the zebrafish DV axis. ACVR1-VSSS had the same signaling behavior
as ACVR1-TSSS in all conditions (compare Fig 3.2A and B, columns 2, 6, 10 and
15). ACVR1-VSSS-R206H similarly retained its ability to over-activate signaling
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in wild-type embryos and rescue Acvr1l deficient embryos (Fig 3.2B, columns 3
and 7). Interestingly ACVR1- VSSS-R206H was more responsive to Bmp7 ligand
(Fig 3.2B, column 11 compared to column 16), compared to ACVR1-TSSSR206H (Fig 3.2A, compare columns 11 to 16). ACVR1-VSSS -G328R was
unable to rescue the C5 phenotype of bmp7-/- embryos (Fig 3.2B, column 12),
but retained the ability to over-activate or rescue signaling in all other conditions
(Fig 3.2B, columns 4, 8, and 17), suggesting it has lost its Bmp7 ligandindependent signaling activity.
Other single GS domain site mutations did not prevent wild-type ACVR1
or FOP-ACVR1 from patterning the zebrafish DV axis either. Similar to the VSSS
mutant, ACVR1-TASS and -TSAS had the same signaling behavior as ACVR1TSSS (Fig 3.2C and D, columns 2, 6, 10 and 15). ACVR1-TASS was ventralizing
in the presence of bmp7 mRNA overexpression (Fig 3.2C, column 15). ACVR1TASS-R206H and -TSAS-R206H also had the same signaling behavior as their
ACVR1-TSSS-R206H counterpart (Fig 3.2C and D, columns 3, 7, 11 and 16).
ACVR1-TASS-G328R, like ACVR1-VSSS-G328R, over-activated or rescued
signaling in all conditions except bmp7-/-. We did not obtain data for ACVR1TSAS-G328R.
These results demonstrate that no single GS domain residue is important
for signaling by ACVR1 or ACVR1-R206H in the presence of Bmp7. Interestingly,
mutation of threonine 189 (VSSS) resulted in a decline in the Bmp7-independent
signaling activity of ACVR1-R206H, and an increase in Bmp7 responsiveness,
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suggesting that this residue may be more important for ligand-independent
signaling. Mutating threonine 189 or serine 190 in the GS domain of ACVR1G328R rendered the receptor unable to signal in the absence of Bmp7 ligand,
suggesting that ACVR1-G328R needs these GS domain serine/threonine
residues to over-activate signaling in the absence of Bmp7 (Table 3.1).

Figure 3.1: The GS domain of ACVR1. The GS domain of ACVR1 occurs from
amino acid 189 to 195. Within this domain are four serine and threonine residues
(Bold, numbered) that are phosphorylated by type II BMP receptors. Residue
R206 (orange, numbered) where the R206H FOP mutation occurs in close
proximity to this domain. In the Following experiments we mutated different
combinations of T189, S190, S192 and S194 within the GS domain to valine and
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alanine (red, bold). VSSS, TASS and TSAS (Fig 3.2); TSAA, TSAS, VSSA and
VASS (Fig 3.3); TAAS, VSAS, TAAA and VAAA (Fig 3.4)
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Figure 3.2: GS mutant ACVR1-R206H, but not -G328R, can signal
independently of Bmp7. (A-D) DV phenotypes of 12-30 hpf wild-type (columns
1-8) or bmp7-/- (columns 9-17) embryos injected with GS domain mutant ACVR1
(purple), ACVR1-R206H (bright red) or ACVR1-G328R (orange) mRNA. The GS
domain of ACVR1, ACVR1-R206H or ACVR1-G328R was mutated to T189V,
S190A, or S192A. GS domain mutants were evaluated for the ability to signal in
four conditions: wild-type embryos (columns 1-4), acvr1l KD (columns 5-8),
bmp7-/- embryos with acvr1l KD (bmp7 null; columns 9-12), and bmp7-/embryos with acvr1l KD and bmp7 mRNA overexpression (bmp7 OE; columns
13-17). The phenotypes evaluated were severe dorsalization (C5-C4, dark blue),
mild dorsalization (C3-C1, light blue), wild-type development (WT, violet), mild
ventralization (V1-V3, light tan), and severe ventralization (V4-V5, dark tan). (A)
ACVR1 (TSSS) injected embryos. Columns: 1, N=382; 2, N=37; 3, N=26; 4,
N=59; 5, N=217; 6, N=56; 7, N=53; 8, N=13; 9, N=240; 10, N=101; 11, N=100;
12, N=56; 13, N=257; 14, N=143; 15, N=120; 16, N=86; 17, N=82. (Bmp7 null
injection data also shown in Chapter 2, Fig 2.3.1). (B) ACVR1T189V (VSSS)
injected embryos. Columns: 1, N=771; 2, N=73; 3, N=134; 4, N=40; 5, N=242; 6,
N=72; 7, N=137; 8, N=37; 9, N=156; 10, N=49; 11, N=65; 12, N=42; 13, N=48;
14, N=55; 15, N=51; 16, N=58; 17, N=39. (C) ACVR1S190A (TASS) injected
embryos. Columns: 1, N=771; 2, N=65; 3, N=15; 4, N=107; 5, N=242; 6, N=78; 7,
N=13; 8, N=74; 9, N=240; 10, N=20; 11, N=5; 12, N=23; 13, N=257; 14, N=143;
15, N=9; 16, N=6; 17, N=8. (D) ACVR1S192A (TSAS) injected embryos. Columns:
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1, N=771; 2, N=38; 3, N=59; 5, N=242; 6, N=31; 7, N=54; 9, N=144; 10, N=49;
11, N=45; 13, N=49; 14, N=55; 15, N=52; 16, N=45.

82

Table 3.1: Bmp7 abundance determines signaling activity of GS domain
mutants. Summary of GS domain mutant ability to signal in the absence of
endogenous Acvr1l and in three different bmp7 conditions: absence of
endogenous bmp7, bmp7-/- (-); endogenous (wild-type) levels of bmp7 (+); and
bmp7-/- with bmp7 mRNA overexpression (++). ACVR1-WT, ACVR1-R206H and
ACVR1-G328R mRNAs had some combination of mutations: T189V, S190A,
S192A, and/or S194A. Signaling was classified as the ability of injected receptor
mRNAs to rescue the C5 dorsalized phenotype to less dorsalized, wild-type, or
ventralized phenotypes. See Figures 3.1-3.3, columns 5-17.

3.4: T189 is important for ligand-independent signaling by ACVR1-R206H
To further investigate the role of the GS domain in signaling by FOPACVR1, we tested GS domain mutants in which some combination of T189,
S190, S192 and S194 were mutated: S192A and S194A (TSAA), S190A and
S194A (TASA), T189V and S194A (VSSA), and T189V and S190A (VASS) (Fig
3.1). Previous work in TGFbR1 showed that loss of two serine/threonine residues
within the GS domain prevented signaling by the receptor (Franzen 1995, Weiser
1995). We tested the function of these GS mutants in 4 different conditions: wildtype, acvr1l KD, bmp7-/- with acvr1l KD, and bmp7-/- with acvr1l KD and bmp7
mRNA overexpression. We evaluated the DV patterning phenotypes of injected
embryos to assay for signaling activity.
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The TSAA and TASA GS domain mutants resembled the single residue
GS domain mutants. The ACVR1-TSAA and -TASA GS domain mutants did not
exhibit altered the signaling activity (Fig 3.3A and B, columns 2, 6, 10 and 15)
compared to ACVR1-TSSS. Similarly, ACVR1-TSAA and TASA -R206H (Fig
3.3A and B, columns 3, 7, 11 and 16) displayed the same signaling behaviors as
ACVR1-TSSS-R206H. ACVR1- TSAA and TASA -G328R behaved like ACVR1TSSS-G328R (Fig 3.3A and B, columns 4, 8, 12 and 17), except they did not
rescue the C5 phenotype of bmp7-/- embryos, similar to the signaling activity of a
single mutated GS domain serine or threonine (Fig 3.2B-D).
Interestingly, VSSA GS domain mutants displayed altered signaling
behavior. ACVR1-VSSA dorsalized zebrafish in the presence of endogenous
Acvr1l, suggesting it caused a dominant negative inhibition of BMP signaling (Fig
3.3C column, 2). This receptor did, however, rescue loss of endogenous acvr1l
(Fig 3.3C, column 6), indicating that it still has signaling activity, but this signaling
activity is deficient compared to wild-type acvr1l. ACVR1-VSSA could not rescue
the C5 phenotype of bmp7-/- embryos, but became ventralizing when the
receptor was overexpressed with bmp7. Similarly, ACVR1-VSSA-R206H was
dorsalizing in the presence of endogenous Acvr1l (Fig 3.3C, column 3), but
rescued Acvr1l KD (Fig 3.3C, column 7), suggesting it also has deficient
signaling activity compared to Acvr1l. Interestingly, unlike other ACVR1-R206H
GS mutants, ACVR1- VSSA-R206H no longer is able to rescue the C5
dorsalized phenotype of bmp7-/- embryos (Fig 3.3C, column 11), however, it was
still ventralizing in the presence of excess Bmp7 (Fig 3.3C, column 16). ACVR184

VSSA-G328R rescued Acvr1l KD (Fig 3.3C column 8), but not bmp7-/- embryos
(Fig 3.3C column 12), consistent with the effects of other ACVR1-G328R GS
mutants.
VASS GS domain mutants also displayed altered signaling behavior.
ACVR1-VASS was dorsalizing in the presence of endogenous Acvr1l (Fig 3.3D
column 2), and did not rescue Acvr1l KD (Fig 3.3D column 6) or bmp7-/- embryos
even with bmp7 overexpression (Fig 3.3D column 10 and 15), suggesting it has
lost all signaling capability. ACVR1-VASS-R206H was dorsalizing in the
presence of endogenous acvr1l (Fig 3.3D column 3), but rescued acvr1l KD (Fig
3.3D column 7), consistent with deficient signaling activity. ACVR1-VASS-R206H
could not rescue bmp7-/- (Fig 3.3D, column 11), but ventralized embryos in the
presence of bmp7 overexpression (Fig 3.3D, column 16). ACVR1-VASS-G328R,
unlike ACVR1-VASS-R206H did not dorsalize embryos in the presence of
endogenous Acvr1l and rescued Acvr1l KD (Fig 3.3D, column 4 and 8), but could
only rescue bmp7-/- embryos in the presence of bmp7 overexpression (Fig 3.3D,
column 12 and 17).
Our data show that ACVR1-VASS, unlike ACVR1-TSAA, -TASA and VSSA, could not signal in any conditions, suggesting that any two of the first
three serine/threonine residues, T189, S190 and S192, is sufficient for the wildtype receptor to signal (Table 3.1). In the context of ACVR1-R206H, our data
suggest that T189 is important for ligand-independent signaling, as both the
TSAA and TASA mutants retained the ability to rescue bmp7-/- mutants. The
ACVR1-VSSA-R206H and VASS-R206H mutants, however, were only able to
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signal in the presence of ligand, suggesting that these GS domain mutations
rendered the receptor ligand-dependent (Fig 3.3A-D). Finally, the signaling
activity of ACVR1-VASS-G328R, -TSAA-G328R, -TASA-G328R and -VSSA G328R (Fig 3.3A-D) was not changed compared to single serine/threonine
ACVR1-G328R GS mutants (Fig 3.2A-C), suggesting that ACVR1-G328R has
altered GS domain serine/threonine residue requirements compared to ACVR1R206H.
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Figure 3.3: T189 is important for ligand-independent signaling. (A-D) DV
phenotypes of 12-30 hpf wild-type embryos (Wild-Type; columns 1-4), wild-type
embryos with acvr1l KD (acvr1l KD; columns 5-8), bmp7-/- embryos with acvr1l
KD (bmp7 null; columns 9-12), and bmp7-/- embryos with acvr1l KD and bmp7
mRNA overexpression (bmp7 OE; columns 13-17) injected with GS domain
mutants ACVR1 (purple), ACVR1-R206H (bright red) or ACVR1-G328R
(orange). The GS domain of ACVR1, ACVR1-R206H or ACVR1-G328R was
mutated to indicated combinations of T189V, S190A, S192A, and/or S194A. (A)
ACVR1S192A,S194A (TSAA) injected embryos. Columns: 1, N=1055; 2, N=86; 3,
N=60; 4, N=60; 5, N=486; 6, N=115; 7, N=73; 8, N=43; 9, N=99; 10, N=26; 11,
N=21; 12, N=10; 13, N=32; 14, N=32; 15, N=9; 16, N=23; 17, N=6. (B)
ACVR1S190A,S194A (TASA) injected embryos. Columns: 1, N=1055; 2, N=20; 3,
N=51; 4, N=84; 5, N=486; 6, N=24; 7, N=39; 8, N=99; 9, N=243; 10, N=47; 11,
N=40; 12, N=33; 13, N=81; 14, N=87; 15, N=55; 16, N=34; 17, N=14. (C)
ACVR1T189V,S194A (VSSA) injected embryos. Columns: 1, N=1055; 2, N=122; 3,
N=41; 4, N=27; 5, N=486; 6, N=120; 7, N=109; 8, N=35; 9, N=243; 10, N=28; 11,
N=64; 12, N=53; 13, N=81; 14, N=87; 15, N=22; 16, N=55; 17, N=59. (D)
ACVR1T189V,S190A (VASS) injected embryos. Columns: 1, N=1055; 2, N=150; 3,
N=109; 4, N=52; 5, N=486; 6, N=136; 7, N=121; 8, N=81; 9, N=99; 10, N=53; 11,
N=63; 12, N=17; 13, N=32; 14, N=32; 15, N=94; 16, N=64; 17, N=8.
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3.5: T189 is not sufficient for ligand-responsive signaling by ACVR1-R206H
We next evaluated additional mutants in which two, three or all four of the
threonine/serines are mutated in some combination: S190A and S192A (TAAS);
T189V and S192A (VSAS); S190A, S192A and S194A (TAAA); and T189V,
S190A, S192A and S194A (VAAA) (Fig 3.1). Previous work in Drosophila
showed that loss of all 4 threonine/serine residues within the GS domain resulted
in loss of signaling by ACVR1-R206H (Le and Wharton 2012). However, cell
culture studies have found that T203, a residue found at the end of the GS
domain, was sufficient for signaling by ACVR1-R206H (Fig 3.1) (Fujimoto, Ohte
et al. 2015). To characterize the signaling ability of our GS domain mutants, we
injected them into wild-type, acvr1 KD, bmp7-/- with acvr1l KD, and bmp7-/- with
acvr1 KD and bmp7 overexpression embryos and evaluated them for DV
patterning phenotypes.
ACVR1-TAAS, -VSAS, -TAAA and -VAAA GS domain mutants could not
pattern the zebrafish DV axis. All four mutants dorsalized embryos in the
presence of endogenous Acvr1l (Fig 3.4A-D, column 2). None of these mutants
could rescue the C5 dorsalized phenotype in Acvr1l KD or bmp7-/- embryos,
regardless of the presence of Bmp7 (Fig 3.4A-D, columns 6, 10 and 15). These
data indicate that ACVR1-TAAS, -VSAS, -TAAA and -VAAA lack the ability to
signal.
FOP-ACVR1 TAAS and VSAS GS domain mutants still retained some
signaling activity. ACVR1-TAAS-R206H, -VSAS-R206H, -TAAA-R206H and VAAA-R206H all dorsalized embryos in the presence of endogenous Acvr1l and
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could not rescue Acvr1l KD embryos (Fig 3.4A-D, columns 3 and 7). These
ACVR1-R206H GS mutants could not rescue bmp7-/- embryos either (Fig 3.4AD, column 11). Interestingly, however, ACVR1-TAAS-R206H and -VSAS-R206H,
but not TAAA-R206H and VAAA-R206H, rescued bmp7-/- embryos with Acvr1l
KD when Bmp7 was overexpressed (Fig 3.4A and B, column 16). Likewise,
ACVR1-TAAS-G328R and VSAS-G328R could signal only with Bmp7
overexpression (Fig 3.4A-D, column 4, 8, 12 and 17). ACVR1-TAAA-G328R, like
ACVR1-TAAA-R206H had no signaling activity in any condition (Fig 3.4A-C,
columns 4, 8, 12 and 17).
These data suggest that at least two residues within the GS domain need
to be phosphorylated for FOP-ACVR1 to signal (Table 3.1). Further, the FOP
mutations R206H and G328R can facilitate signaling by the TAAS and VSAS GS
domain mutants only in the presence of Bmp7 ligand overexpression, suggesting
that these mutants are also dependent on ligand for signaling. T189 while
important for ligand-independent signaling, is not sufficient for signaling by FOPACVR1 regardless of ligand overexpression.
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Figure 3.4: T189 is not sufficient for ligand-dependent signaling. (A-D) DV
phenotypes of 12-30 hpf wild-type embryos (Wild-Type; columns 1-4), wild-type
embryos with acvr1l KD (acvr1l KD; columns 5-8), bmp7-/- embryos with acvr1l
KD (bmp7 null; columns 9-12), and bmp7-/- embryos with acvr1l KD and bmp7
mRNA overexpression (bmp7 OE; columns 13-17) injected with GS domain
mutants ACVR 1(purple), ACVR1-R206H (bright red) or ACVR1-G328R
(orange). The GS domain of ACVR1, ACVR1-R206H or ACVR1-G328R was
mutated to indicated combinations of T189V, S190A, S192A, and/or S194A. (A)
ACVR S190A,S192A (TAAS) injected embryos. Columns: 1, N=1055; 2, N=33; 3,
N=66; 4, N=101; 5, N=486; 6, N=38; 7, N=45; 8, N=101; 9, N=99; 10, N=35; 11,
N=40; 12, N=37; 13, N=32; 14, N=32; 15, N=36; 16, N=24; 17, N=34. (B)
ACVR1T189V,S192A (VSAS) injected embryos. Columns: 1, N=1055; 2, N=175; 3,
N=58; 4, N=83; 5, N=556; 6, N=180; 7, N=54; 8, N=81; 9, N=243; 10, N=52; 11,
N=53; 12, N=17; 13, N=81; 14, N=87; 15, N=52; 16, N=40; 17, N=5. (C)
ACVR1S190A,S192A,1904A (TAAA) injected embryos. Columns: 1, N=880; 2, N=61; 3,
N=104; 4, N=139; 5, N=330; 6, N=69; 7, N=113; 8, N=141; 9, N=187; 10, N=13;
11, N=36; 12, N=46; 13, N=74; 14, N=89; 15, N=20; 16, N=32; 17, N=53. (D)
ACVR1T189V,S190A,S192A,S194A (VAAA) injected embryos. Columns: 1, N=199; 2,
N=78; 3, N=34; 5, N=83; 6, N=33; 7, N=51; 9, N=156; 10, N=17; 11, N=21; 13,
N=49; 14, N=59; 15, N=22; 16, N=10.
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3.6: ACVR1-TSAA-R206H and ACVR1-VASS-R206H both signal in the
absence of all other type I BMP receptors
In the zebrafish, Bmp2/7 ligand is critical for the association of Acvr1l with
Bmpr1 and type II BMP receptors (Little and Mullins 2009). The requirement of
ligand by certain GS domain FOP-ACVR1 mutants suggests that these mutants
also require complex assembly. To test if there is a differential type I receptor
requirement between our ligand-independent and ligand-dependent ACVR1R206H GS domain mutants, we injected ACVR1-TSAA-R206H and ACVR1VASS-R206H into zebrafish embryos deficient for all type I BMP receptors. To
generate a zebrafish deficient for all type I BMP receptors, we intercrossed
bmpr1aa+/-, bmpr1ab-/- zebrafish and injected their embryos with MOs against
bmpr1ba, bmpr1bb and acvr1l (designated as Type I KD embryos). We then
injected these embryos with mRNAs for our ligand-independent GS domain
mutant, ACVR1-TSAA-R206H, or our ligand-dependent GS domain mutant,
ACVR1-VASS-R206H, with or without bmp7 mRNA overexpression.
Normally Bmpr1 is required to pattern the DV axis of the developing
zebrafish. Type I KD embryos are severely dorsalized to a C5 phenotype (Fig
3.5A and B, column 9) and this C5 phenotype cannot be rescued by bmp7
overexpression (Fig 3.5A and B, column 10). As expected, ACVR1-TSAA-R206H
over-activated signaling and ventralized Type I KD embryos with or without bmp7
overexpression (Fig 3.5A, columns 11 and 12). ACVR1-VASS-R206H did not
rescue Type I KD embryos in the presence of endogenous levels of bmp7 (Fig
3.5B, column 11). Interestingly, when bmp7 was overexpressed ACVR1-VASS93

R206H was able to ventralize Type I KD embryos (Fig 3.5B, column 12),
suggesting that this mutant receptor can respond to increased levels of ligand
without type I BMP receptor partners. These data show that both a ligandindependent and ligand-dependent ACVR1-R206H receptor can signal in the
absence of type I BMP receptor partners. These results imply that ligandresponsive ACVR1-R206H has acquired the ability to respond to ligand without
its normal BMP receptor complex.

Figure 3.5: Acvr1-R206H ligand-independent and ligand-dependent GS
mutants do not require any other type I BMP receptors to signal. A and B)
DV phenotypes of 12-30 hpf bmpr1a+/- or -/- embryos injected with bmpr1b KD,
acvr1 KD with or without ACVR1-S192A,S194A,R206H (ACVR1-R206H TSAA;
ligand-independent GS mutant) or ACVR1T-189V,S190A,R206H (ACVR1R206H VASS; ligand-dependent GS mutant) mRNA with bmp7 mRNA. (A)
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Columns: 1, N=7; 2, N=6; 3, N=10; 4, N=13; 5, N=13; 6, N=16 ;7, N=34; 9, N=3;
10, N=9; 11, N=13; 12, N=3. (B) Columns: 1, N=7; 2, N=6; 3, N=10; 4, N=13; 5,
N=27; 6, N=17; 7, N=34; 9, N=3; 10, N=9; 11, N=13; 12, N=13.

3.7: FOP-ACVR1 requires ATP binding to signal
GS domain phosphorylation is thought to result in a conformational
change to the kinase domain of type I BMP receptors that allows for ATP and
Smad1/5 binding (Sanvitale, Kerr et al. 2013). FOP-ACVR1 induced changes to
the GS domain conformation may alter ATP binding to the mutant receptor
(Chaikuad, Alfano et al. 2012). Several small molecule ATP competitive binding
inhibitors (SMIs) have been developed to inhibit the signaling activity of type I
BMP receptors including DMH1, an inhibitor of all type I BMP receptors, and
K02288, a highly specific inhibitor for ACVR1 (Sanvitale, Kerr et al. 2013,
Mohedas, Wang et al. 2014). Both of these inhibitors are based on the structure
of Dorsomorphin, and have been shown to mitigate overactive signaling by FOPACVR1 in vitro (Yu, Deng et al. 2008, Yu, Hong et al. 2008, Mohedas, Wang et
al. 2014, Williams and Bullock 2018). To test if FOP-ACVR1 was still susceptible
to competitive ATP binding inhibitors in our system, we treated FOP-ACVR1
injected embryos with DMSO, DMH1, or K02288. Embryos were then evaluated
for DV patterning phenotypes or immunostained for pSmad1/5.
DMH1 dose-dependently dorsalized uninjected wild-type embryos (Fig
3.6A). As expected, embryos injected with ACVR1-R206H were severely
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ventralized showing that the mutant receptor over-activates BMP signaling.
Treatment with DMH1 rescued ACVR1-R206H injected embryos to less
ventralized phenotypes or dorsalized them. Similarly, embryos injected with
ACVR1 or ACVR1-G328R were dorsalized by treatment with DMH1 (Fig 3.6B).
Uninjected wild-type embryos had a pSmad1/5 gradient that peaks ventrally and
decreases dorsally (Fig 3.6C) (Schmid, Furthauer et al. 2000, Mintzer, Lee et al.
2001, Zinski, Bu et al. 2017, Zinski, Tuazon et al. 2019). This pSmad1/5 gradient
is expanded in embryos injected with ACVR1-R206H or -G328R. pSmad1/5
intensity in all of these embryos was reduced or eliminated by treatment with
DMH1.
Treatment with the more specific ACVR1 inhibitor, K02288, also dosedependently dorsalized uninjected wild-type embryos (Fig 3.6D). Interestingly,
wild-type embryos were less sensitive to treatment with K02288 compared to
DMH1. ACVR1-R206H injected embryos treated with K02288 were rescued to
less severe phenotypes or dorsalized. Similarly, embryos injected with ACVR1 or
ACVR1-G328R were also dorsalized by K02288 (Fig 3.6E). Uninjected wild-type
embryos did not display a difference in pSmad1/5 gradient intensity upon
treatment with low levels of K02288 (Fig 3.6F). ACVR1-R206H injected embryos,
however, showed a strong reduction in pSmad1/5 signaling intensity with K02288
treatment. These results suggest that human ACVR1 is more sensitive to the
K02288 inhibitor than zebrafish Acvr1l. Human and zebrafish receptors vary in a
single amino acid residue within the ATP binding pocket that interacts with this
small molecule inhibitor (M288 in the human, N285 in the zebrafish) (Sanvitale,
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Kerr et al. 2013). Taken together, these data show that inhibition of the kinase
activity of FOP-ACVR1 is sufficient to prevent pSmad1/5 over-activation and
ventralization of zebrafish.

Figure 3.6: ACVR1-R206H and -G328R require ATP binding to over-activate
signaling. A,B) DV phenotypes of 12-30 hpf wild-type embryos injected with
nothing (white), ACVR1 (purple), ACVR1-R206H (red) or ACVR1-G328R
(orange) mRNA and treated with the small molecule kinase inhibitor DMH1.
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(A) Columns: 1, N=50; 2, N=52; 3, N=40; 4, N=39; 5, N=40; 6, N=35; 7, N=41; 8,
N=45; 9, N=59; 10, N=39; 11, N=38; 12, N=43; 13, N=45; 14, N=28.
(B) Columns: 1, N=20; 2, N=41; 3, N=20; 4, N=18; 5, N=20; 6, N=17; 7, N=21.
(C) Animal pole view of relative pSmad1/5 intensities (arbitrary units (AU)) within
each nucleus in representative WT early-gastrula embryos injected with nothing,
ACVR1-R206H or ACVR1-G328R and treated with DMH1. Embryos are oriented
with the ventral (V) side to the left and the dorsal (D) side to the right, when
known.
(D,E) DV phenotypes of 12-30 hpf wild-type embryos injected with nothing
(white), ACVR1 (purple), ACVR1-R206H (red) or ACVR1-G328R (orange) mRNA
and treated with the ACVR1 specific small molecule kinase inhibitor K02288. (D)
Columns: 1, N=50; 2, N=52; 3, N=42; 4, N=54; 5, N=58; 6, N=40; 7, N=29; 8,
N=45; 9, N=59; 10, N=40; 11, N=59; 12, N=46; 13, N=22; 14, N=17 (E) Columns:
1, N=20; 2, N=41; 3, N=19; 4, N=22; 5, N=20; 6, N=14; 7, N=16.
(F) Animal pole view of relative pSmad1/5 intensities (AU) within each nucleus in
representative WT early-gastrula embryos injected with nothing or ACVR1R206H and treated with K02288. Embryos are oriented with the ventral (V) side
to the left and the dorsal (D) side to the right.
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3.8: The human ACVR1 kinase domain is sufficient to facilitate overactive
signaling by Acvr1l-R203H
Previous studies showed that despite the high conservation of the GS
domain between human and zebrafish receptors, zebrafish Acvr1l-R203H (the
paralogue to ACVR1-R206H) does not over-activate signaling (Fig 3.7A) (Mullins,
unpublished data). Interestingly acvr1l-G325R (paralogue of ACVR1-G328R)
does over-activate signaling, suggesting something about the zebrafish GS
domain prevents the R203H mutation from causing overactive signaling. To
determine if parts of the human receptor could facilitate overactive signaling to
the zebrafish receptor, we generated chimeras in which the intracellular domain
of Acvrl1-R203H was replaced with that of the human ACVR1-R206H receptor.
We then tested the ability of these mutants to rescue the C5 dorsalized
phenotype of Acvr1l KD embryos.
Human ACVR1 and zebrafish Acvr1l are both able to pattern the DV axis.
When Acvr1l is deficient, zebrafish embryos are severely dorsalized (Fig 3.7A,
column 2). Zebrafish acvr1l and acvr1l-R203H rescued loss of acvr1l, but did not
ventralize zebrafish beyond a possible mild V1 phenotype (Fig 3.7A, columns 36). Because morpholino injection causes apoptosis of neural tissue, the reduced
eye size of the acvr1l MO-injected V1 embryos may be attributable to MO
background, rather than ventralization, since it is not observed in the acvr1l or
acvr1l-R203H-injected embryos without the MO (Fig 3.7A, columns 3 and 5).
Thus, neither acvr1l nor acvr1l-R203H over-activate signaling and ventralize
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zebrafish embryos. Human ACVR1 was able to rescue deficiency of Acvr1l, and
mildly ventralized zebrafish to a V1 phenotype. ACVR1-R206H, however, overactivated signaling and ventralized zebrafish embryos to a V5 phenotype
regardless of the presence of acvr1l (Fig 3.7A, columns 7-10), demonstrating that
this mutation is activating in the human receptor.
Both our human-zebrafish chimeras are able to ventralize developing
zebrafish. As expected, the zebrafish-human chimera ACVR1-R206H ZZHH,
which contains the zebrafish extracellular and transmembrane domains, and the
human GS and kinase domains, severely ventralized embryos regardless of the
presence of endogenous Acvr1l (Fig 3.7B and B’). Interestingly, ACVR1-R203H
ZZZH, which contains the zebrafish extracellular, transmembrane and GS
domains, and the human kinase domain, also over-activated signaling and
severely ventralized embryos regardless of the presence of endogenous Acvr1l
(Fig 3.7C and C’). These data demonstrate that the human kinase domain is
sufficient to make Acvr1l-R203H ventralizing, and suggest that interaction
between the GS and kinase domains is critical for the pathogenesis of FOP.
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Figure 3.7: The human ACVR1 kinase domain is sufficient to facilitate
overactive signaling by zebrafish Acvr1-R203H. (A-C) DV phenotypes of 1230 hpf wild-type embryos with acvr1l KD injected with zebrafish (z,Z) acvr1l
(yellow stripes), human (h,H) ACVR1 (green), or chimeric zebrafish-human
ACVR1 (green/yellow checked). (A) Embryos with acvr1l KD injected with
zacvr1l, zacvr1l-R203H, hACVR1, hACVR1-R206H. Columns: 1, N=130; 2,
N=102; 3, N=51; 4, N=44; 5, N=19; 6, N=25; 7, N=37; 8, N=56; 9, N=26; 10,
N=53. (Data also shown in Fig 1). (B) Embryos with acvr1l KD injected with
ACVR1-R206H ZZHH chimera (zebrafish extracellular and transmembrane
domains with human GS and kinase domains). The FOP R206H mutation is
within the human GS domain. Columns: 1, N=13; 2, N=12; 3, N=30; 4 N=29. (B’)
Representative 12 and 30 hpf phenotypes. (C) Embryos with acvr1l KD injected
with ACVR1-R203H ZZZH chimera (zebrafish extracellular, transmembrane and
GS domains, and human kinase domain). The FOP R203H mutation is in the
zebrafish GS domain. Columns: 1, N=50; 2, N=36; 3, N=56; 4, N=61. (C’)
Representative 12 and 30 hpf phenotypes.

3.9: Discussion
Using an in vivo zebrafish development model as an assay for BMP
signaling, we show for the first time that ligand-responsive and ligandindependent signaling through FOP-ACVR1 receptors have a differential
requirement for serine/threonine residues within the GS domain. We found that
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the signaling activity of our GS domain mutants fell into four distinct categories:
non-signaling, deficient-signaling (rescued Acvr1l KD, but was dorsalizing in wildtype embryos), ligand-dependent (only signaled in the presence of Bmp7) and
ligand-independent (rescued bmp7-/- mutants). The ability of these mutants to
signal in response to different levels of Bmp7 is summarized in Table 1. Neither
the ligand-independent GS mutant, ACVR1-TSAA-R206H, nor the liganddependent ACVR1-VASS-R206H, required other type I BMP receptors for their
activity. Additionally, we confirmed that competitive ATP binding inhibitors
abrogated overactive signaling by FOP-ACVR1. Finally, we show that the human
ACVR1 kinase domain is sufficient to allow Acvr1l-R203H to over-activate
signaling, demonstrating that the GS and kinase domains have highly
coordinated activity and this coordination is integral to the pathogenesis of FOP.
Our results demonstrate that both wild-type ACVR1 and ACVR1-R206H
require two of four serine/threonine residues within the GS domain to signal.
TGFbR1 was previously found to lack signaling activity if two or more
serine/threonine residues were mutated (Franzen, Heldin et al. 1995, Wieser,
Wrana et al. 1995), suggesting that ACVR1 has a lower GS domain activation
threshold than TGFbR1. The wild-type ACVR1 GS mutants that retained the
ability to signal had two of T189, S190 and S192. S194 in combination with
another serine or threonine, however, appeared to be insufficient to allow wildtype ACVR1 to signal. Conversely, ACVR1-R206H and -G328R can signal with
the TAAS, VSAS, and VASS GS domain mutations, suggesting that the FOP
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mutations compensate for reduced GS domain activatability. However, these
ACVR1-R206H and -G328R GS domain mutants depend on BMP ligand for
signaling. It is important to note that although valine and alanine are highly
structurally similar to threonine and serine, respectively, unlike threonine and
serine, they are non-polar. We cannot exclude that changes in the charge of
amino acids within the GS domain may lead to unexpected changes in protein
conformation.
Interestingly, we found that some GS domain mutants retained the ability to
signal in the absence of ligand, while others could only signal in the presence of
Bmp7 ligand. Because ligand is critical for the assembly of type I and II BMP
receptors, the ability to signal in the absence of ligand suggests an ability to
signal in the absence of complex assembly. However, our results and others
demonstrate that presumptive phosphorylation of the GS domain is still required
for activation of ACVR1-R206H (Le and Wharton 2012, Bagarova, Vonner et al.
2013, Hino, Ikeya et al. 2015). Our data show that only two serine/threonine
residues are required and that T189 is important for ligand-independent signaling
by ACVR1-R206H. T189 may be the residue within the GS domain that is most
accessible for free type II receptors to phosphorylate upon stochastic interaction
with ACVR1-R206H. The FOP mutations have been shown to displace the type I
BMP receptor inhibitor FKBP12 (Chen, Liu et al. 1997, Shen, Little et al. 2009,
van Dinther, Visser et al. 2010, Chaikuad, Alfano et al. 2012, Machiya,
Tsukamoto et al. 2018), which may allow these GS domain residues to be
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accessible to phosphorylation. Previous studies showed that loss of ACVR1R206H signaling in the absence of type II receptors could be rescued with only
the extracellular domain of a type II receptor (Bagarova, Vonner et al. 2013).
These studies proposed that GS domain activation of type I receptors occurred
by transphosphorylation by other type I receptors or by autophosphorylation by
ACVR1 itself. T189 may be the residue most amenable to phosphorylation by
these possible other mechanisms, and combined with the FOP mutation lowers
the activation threshold of ACVR1-R206H in the absence of ligand (Shore and
Kaplan 2010).
We found that no specific residues are required for ligand-dependent
signaling. However, within our group of ligand-dependent FOP-ACVR1 GS
domain mutants, were two further sub-groups: mutants that signaled with
endogenous levels of Bmp7 (VSSA and VASS) and mutants that required Bmp7
overexpression to signal (TAAS and VSAS) (Table 1). Excess ligand was not
sufficient to allow any non-signaling wild-type ACVR1 GS mutants to signal,
suggesting that the FOP mutation does indeed act to reduce the GS domain
phosphorylation requirements for activation of the receptor. Interestingly ACVR1VASS-R206H, a GS domain mutant that requires ligand to signal, still overactivated signaling in the absence of all other type I BMP receptors. These data
suggest that ACVR1-R206H has acquired the ability to respond to Bmp7 ligand
without BMPR1.
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ACVR1-R206H may also have acquired the ability to signal with other type I
TGFb receptors in response to ligand (Ramachandran, Vizan et al. 2018).
Alternately, receptor complexes with the type II BMP receptors alone may be
sufficient for ACVR1-R206H, but not ACVR1, to respond to ligand. Previous
experiments in cell culture found that T203 alone was sufficient to allow ACVR1VAAA-R206H to signal in the presence of excess type II BMP receptors
(Fujimoto, Ohte et al. 2015), suggesting that type II BMP receptors may be
sufficient to complex with ACVR1-R206H alone. These data further corroborate
that activation of ACVR1 does not require all the residues within the GS domain
to be phosphorylated, and that increasing the likelihood of a phosphorylation
event, through either overexpression of ligand or overexpression of a type II BMP
receptor, can compensate for loss of serine/threonine residues.
Interestingly, unlike ACVR1-R206H, all ACVR1-G328R GS domain mutants
became dependent on ligand to signal. Previous studies have found that ACVR1G328R appears to be more responsive to ligand than ACVR1-R206H (Chapter 2)
(Haupt, Xu et al. 2018). Our data support that kinase domain mutations overactivate signaling through ACVR1 by subtly different mechanisms.
We showed that ATP binding competitive inhibitors abrogated signaling by
FOP-ACVR1. The FOP mutants do not appear to be protective against ATP
binding inhibitors, suggesting that ATP binding remains a necessary component
of mutant ACVR1 signaling. Interestingly, human ACVR1 appeared to be more
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sensitive to the ACVR1-specific small molecule inhibitor K02288 than zebrafish
Acvr1l.
Finally, our data show that interaction between the GS domain and kinase
domain is critical for the pathogenesis of FOP. We found that Acvr1l-R203H, the
zebrafish paralog to ACVR1-R206H, does not over-activate the BMP signaling
pathway. Unexpectedly, when the kinase domain of Acvr1l-R203H was replaced
by the human ACVR1 kinase domain, this receptor became over-activating.
Immediately downstream of the kinase domain of ACVR1 is an Ca-loop
structure, believed to be important for inhibition of kinase activity, that is
displaced upon GS domain phosphorylation (Chaikuad, Alfano et al. 2012,
Sanvitale, Kerr et al. 2013, Mohedas, Wang et al. 2014). The human kinase
domain may have a “less-inhibitory” Ca-loop or the conformation of the human
kinase domain has differential sensitivity to GS domain FOP mutations compared
to zebrafish Acvr1l-R203H. These data confirm that the interaction between the
GS domain and other parts of the ACVR1 receptor are critical for this mutation to
over-activate signaling.
Our results support that FOP-ACVR1 has a lower activation threshold to
initiate signaling than wild-type ACVR1 (Shore and Kaplan 2010). Our studies
support that the lower activation threshold corresponds to a lower GS domain
activation threshold. Heterotopic ossification in FOP has been reported to occur
both spontaneously and in response to inflammation. Our Bmp7 ligand
overexpression condition may parallel the cascades of ligand that occur during
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an inflammatory event. The lower activation threshold in the presence of excess
ligand may result in sustained overactive signaling in an inflammatory event.
Even in the absence of ligand, however, the receptor still exhibits a reduced
requirement for GS domain phosphorylation, which would also account for
overactive signaling resulting in spontaneous heterotopic ossification. These data
demonstrate the power of the embryonic zebrafish development system as an
assay for FOP-ACVR1 activity. Further studies into the interactions between the
FOP mutations and the rest of the ACVR1 receptor will give insight into how
these mutations lead to overactive BMP pathway signaling and disease.
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CHAPTER 4: Materials and Methods
4.1: Zebrafish
Procedures involving animals were approved by the University of
Pennsylvania IACUC. Adult zebrafish were kept at 28oC in a 13-hr light/11-hr
dark cycle. All zebrafish husbandry was performed in accordance with
institutional and national ethical and animal welfare guidelines. The characterized
mutant bmp7sb1aub (bmp7-/-)(Schmid, Furthauer et al. 2000) and bmpr1aa+/- in a
bmpr1ab-/-sa0028 mutant background were used in this study. bmpr1aa was
mutated by Benjamin Tajer (Mulilns Lab) using CRISPR-Cas9 genome editing.
bmp7sb1aub fish were maintained as homozygous mutant stocks by rescuing the
C5 dorsalized embryonic phenotype with bmp7 mRNA injection. bmpr1aa+/;bmpr1ab-/- fish were generated by intercrossing and genotyping for the bmpr1aa
allele (described below). Embryos used in these experiments were 0-48 hpf.
Embryos were raised at 28-32oC in E3 solution. Sex/gender was not accounted
for as zebrafish sex determination takes place later in juvenile stages of
development (Santos, Luzio et al. 2017).
4.2: Genotyping
Adult and embryonic genomic DNA was obtained using HotShot DNA
isolation. Genotyping of adults and embryos for bmpr1aa was performed using
KASPar genotyping (Smith and Maughan 2015). Primers were designed and
synthesized by LGC Bioscience Technologies. The following sequence was
submitted for primer design:
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ATAAGAGGAGTCAGGAGTGATCTCTTTAACATCAAGGATA[CNAAAAAAACA
GCTTTGACTGTGTTTTGTCATCAGGTATAAGTGGCAGACAGA/GTCCGTTATC
AACTTGAAAAAGTGGCACC]GAGGCAGCGCTACCACAGAGACCTGGAGCAA
GACGAGGCCTTTATCCCAGCAGGAGAATCCCTGAAAGA (Primer sequences
are proprietary, LGC Biosearch technologies). Immunostained embryos were
recovered after photographing and placed in methanol prior to Hotshot and
KASPar genotyping. Alternatively, bmpr1aa mutant fish are genotyped by
conventional PCR using Choice Taq Blue Mastermix (Denville CB4065-7), and
the following primers.
Forward: AGAGGAGTCAGGAGTGATCTCTTT
Reverse: TTGATGAGGTCTTTCAGGGATT
4.3: Site directed mutagenesis
GS domain mutants were generated using site directed mutagenesis.
Mutagenesis PCR was performed using AccuPrime Pfx high fidelity DNA
polymerase (Invitrogen). Mutations were sequentially introduced up to four
residues at a time using the following primers:
VSSS F
R
TASS F
R
TSAS F
R
TSAA F
R
TASA F
R
VSSA F
R

GGATCATTCGTGTGTATCAGGAAGTGGCTCTGG
GGAAGACCAGAGCCACTTCCTGATACACACG
GGATCATTCGTGTACAGCAGGAAGTGGCTCTGG
GGAAGACCAGAGCCACTTCCTGCTGTACACG
CGTGTACATCAGGAGCTGGCTCTGGTCTTCC
CCAGAGCCAGCTCCTGATGTACACGAATGATCC
CGTGTACATCAGGAGCTGGCGCTGGTCTTCCTTTTC
GTACCAGAAAAGGAAGACCAGCGCCAGCTCCTG
GTACAGCAGGAAGTGGCGCTGGTCTTC
GAAAAGGAAGACCAGCGCCACTTCCTG
CGTGTGTATCAGGAAGTGGCGCTGGTCTTCC
GAAAAGGAAGACCAGCGCCACTTCCTGATAC
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VASS F
R
TASA F
R
VSAS F
R
TAAA F
R
VAAA F
R

GGATCATTCGTGTGTAGCAGGAAGTGGCTCTGG
GGAAGACCAGAGCCACTTCCTGCTACACACG
CATTCGTGTACAGCAGGAGCTGGCTCTGGTC
GGAAGACCAGAGCCAGCTCCTGCTGTAC
CGTGTGTATCAGGAGCTGGCTCTGGTCTTC
GAAAAGGAAGACCAGAGCCAGCTCCTGATAC
GGATCATTCGTGTACAGCAGGAGCTGGCGCTGG
GGAAGACCAGCGCCAGCTCCTGCTGTACACG
GGATCATTCGTGTGTAGCAGGAGCTGGCGCTGG
GGAAGACCAGCGCCAGCTCCTGCTACACACG

4.4: Infusion cloning
Human-zebrafish ACVR1 chimeras were generated using infusion cloning.
ACVR1 fragments were amplified using PfuUltra high fidelity polymerase
(Agilent) and the following primers:
Zebrafish
exons 1-4
Zebrafish
exons 1-5
Human exon 5end
(with V5 tag)
Human exon 6end
(with V5 tag)

F
R
F
R
F
R

CTTTTTGCAGGATCCATGGGGCATTGCAGCACCCAAATC
CACGAATGATCCAATAAATCCGCAAGTGTGCTGTCTCCGA
CTTTTTGCAGGATCCATGGGGCATTGCAGCACCCAAATC
TCGGAGACAGCACACTTGCGGATTTATTGGATCATTCGTG
CTCACCATACCTGCCTTTCCAACACACTCCACCAGGCTGA
AGAGGGTTAGGGATAGGCTTACCGTCAGTTTTCAATTTGTCGA

F TCAGCCTGGTGGAGTGTGTTGGAAAGGCAGGTATGGTGAG
R AGAGGGTTAGGGATAGGCTTACCGTCAGTTTTCAATTTGTCGA

Fragments were then combined and inserted into pCS2+ expression vector using
the InFusion HD cloning plus kit (Takara; Cloned by Maya Hale with consultation
from Benjamin Tajer).
4.5: mRNA synthesis
Human, mouse, or zebrafish ACVR1 cDNAs were cloned into the pCS2+
expression vector. mRNA was synthesized using sP6 mMessage machine kit
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(Sigma Aldrich) and purified using phenol:chloroform extraction. mRNAs were
stored in nuclease-free water at -80o C.
4.6: Microinjection of 1-cell stage zebrafish embryos
Eggs 0-15 minute post fertilization were collected in E3 media and injected
at 22oC. For each experiment, each mRNA was injected into eggs with the same
calibrated needle. For serial injections, eggs were loaded onto the same plate
and injected with the first mRNA or morpholino, a subset were then set aside for
controls and the remainder were injected with the next mRNA or morpholino.
This process was repeated multiple times in different orders to ensure
consistency between experimental and control conditions. Injection
concentrations of each mRNA were determined based on phenotypic evaluation.
In cases in which multiple mRNA syntheses were used, different mRNA
concentrations were used to achieve the same phenotype due to presumed
inconsistent mRNA 5’ capping. Working concentrations of mRNA based on
Nanodrop spectrometer measurements: 30-250 pg mAcvr1 and DmAcvr1
mRNAs, 65-250 pg hACVR1 mRNAs, 100-300pg GS domain mutant mRNAs,
100-300pg human-zebrafish chimera mRNAs, 1 ng chordin mRNA, 200 pg bmp7
for rescue of bmp7-/- to a wildtype phenotype, 500 pg-1 ng of bmp7 was used for
overexpression experiments. Morpholinos were synthesized by Gene Tools LLC
and reconstituted in Daneaue solution at 25 mg/ml. A morpholino mixture of
2.3ng Alk8MO2 (5’TGCCTTTCAGTATTCGCACAGCCAG3’) and 9.2ng Alk8MO3
(5’GATTCATGTTTGTGT3’) was used to knockdown endogenous acvr1l. To
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knock down all the type I BMP receptors 17 ng Alk8MO3 was coinjected with a
mixture of 5ng Alk6aMO1 (5’AGAACTCCAGTGAGCCAGAGAATCC3’) and 2ng
Alk6bMO5 (5’GCATGGAAACACTCTCACACACACA3’).
4.7: Small molecule inhibitor treatment
The small molecule ATP competitive binding inhibitors (SMIs), DMH1 and
K02288, were diluted to 50uM stocks in DMSO. Embryos were injected with
mRNAs and treated with SMIs or DMSO in E2 media from starting at 2 hpf and
then collected at early gastrulation for immunostaining or evaluated for DV
patterning phenotypes at 30 hpf.
4.8: Phenotypic evaluation
Embryos between 12 to 48 hpf were categorized into dorsoventral
patterning phenotypes (Fig1g). All images of embryos were photographed in E3
media with a Leica IC80HD. Injection results and controls from multiple
experiments were then pooled. Background was subtracted in phenotype
pictures using Image J, and white balance adjusted using Adobe Photoshop.
4.9: Immunofluorescence
P-Smad1/5 immunostaining and imaging were performed as previously
described (Zinski, Bu et al. 2017, Zinski, Tuazon et al. 2019). For all
immunostaining, embryos were fixed in 4% formaldehyde in PBST between
shield stage and 60% epiboly (approximately 6-7 hpf), blocked with 10% FBS in
PBST, and probed overnight at 4o C with a 1:200 dilution of anti-PSmad1/5/9
(Cell Signaling 13820), 1:100 of anti-HA (Invitrogen 71-5500), 1:100 of anti-Flag
(Sigma F7425), and/or 1:1000 of anti-beta-Catenin (Sigma C7207) diluted in
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blocking solution. Embryos were then treated overnight at 4oC with a 1:500
dilution of antibody Alexa 647 (Invitrogen A-21245), 1:500 of Alexa 546
(Molecular Probes A21123), and/or 1:2000 of Sytox green (Fisher S7020) diluted
in blocking solution. Stained embryos were stored in the dark at 4oC in PBST for
up to 2 months.
4.10: Immunofluorescence Imaging and analysis
Prior to imaging, immunostained embryos were gradually dehydrated in
MeOH and then cleared using BABB: a 1:2 ratio of benzyl alcohol (Sigma B-104)
and benzyl benzoate (Sigma B-6630). Whole embryos were mounted with the
DV axis parallel to the cover slip (either animal pole up or down). Imaging was
performed using a Ziess LSM880 confocal microscope with an LD LCI PlanAchromat 25X/0.8 lmm Corr DIC M27 multi-immersion lens in the oil-immersion
setting. A single bead from a calibration slide (ThermoFisher Scientific
Cat#F369009, Well A1) was imaged between each slide of embryos to account
for fluctuations in laser power over time. Immunoflourescence was performed as
described in Zinski et al. 2017, with the following changes: embryos were imaged
in a single 225x225 um frame and pixel dwell time was reduced to 0.77usec.
Mean fluorescence of each fluorescent bead stacked image was
measured using Imaris statistical analysis. Fold change in mean fluorescence
was then calculated for each bead compared to a reference bead that was
imaged immediately after an uninjected embryo was imaged. The fold change in
mean fluorescence was then applied to the total fluorescence of each
experimental imaged embryos using the ImageJ multiply function. Calibrated
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Images were analyzed using the Imaris software spots function which identifies
each nucleus within the immunostained embryo using the Sytox green nuclear
stain and refined based on size (4.5 um) and quality. Spot quality threshold is set
using a control image to allow the program to detect all nuclei without detecting
fluorescent points that are not nuclei. For these experiments, the spots function
was set using an uninjected WT embryo and then applied to each experimental
embryo. The Imaris program was then used to color each spot based on mean
relative pSmad1/5 (Alexa 647) intensity (AU) within the spot.
4.11: In situ hybridization
Whole mount in situ hybridizations were performed on fixed 5-9 somite
stage embryos using DIG-labeled anti-sense RNA probes (made with labeling kit:
Roche 11277073910) to pax2.1, krox20, and myod. Probes were visualized with
anti-DIG-Alkaline Phosphatase (Roche11093274910) and developed in BM
Purple (Roche 11442074001). Embryos were mounted on agarose in methanol
and photographed with a Leica IC80HD. Images were processed using image J.
After imaging, embryos were collected in MeOH for genotyping.
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Chapter 5: Discussion and Future Directions
5.1: Summary
The data presented in this thesis demonstrate how the study of rare
disease gives insight into biological functions by showing how they can be
altered. Fibrodysplasia ossificans progressiva (FOP) presents a unique situation
in which a single missense mutation fundamentally alters the ligand-receptor
complex requirement of the type I BMP receptor, ACVR1. We found that, unlike
wild-type ACVR1, FOP-ACVR1 has both ligand-independent and ligandresponsive activity, and neither of these signaling modalities require any other
type I BMP receptors (Fig 5.1; Chapter 2). Both these signaling modalities
require ATP binding, but they have differential GS domain phosphorylation
requirements (Chapter 3). In particular while T189 is important for ligandindependent signaling by ACVR1-R206H, ligand-responsive signaling by this
receptor does not require T189. In addition, we found that unlike ACVR1-R206H,
loss of any GS domain serine/threonine residues renders ACVR1-G328R unable
to signal independent of ligand, demonstrating that the effects of these two
mutations differ. By understanding how these two mutations lead to disease, we
can further elucidate how ACVR1 is regulated normally.
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Figure 5.1: Signaling modalities of ACVR1-R206H. In zebrafish DV patterning
wild-type Acvr1l signaling requires the assembly of a receptor heterotetramer
consisting of two type I BMP receptors, Acvr1l and Bmpr1, and two type II BMP
receptors around a Bmp2/7 ligand heterodimer. Ligand responsive signaling by
ACVR1-R206H does not require Bmpr1, and can signal with any combination of
two serine/threonine residues within the GS domain. Ligand independent
signaling by ACVR1-R206H does not require Bmpr1 or the ligand binding domain
of ACVR1 itself but does require at least two serine/threonine residues within the
GS domain, one of which must be T189.
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5.2: The role of the BMP ligand-receptor signaling complex in FOP
Our and other studies have shown that ACVR1-R206H can signal in the
absence of BMP ligand and ligand binding (Shen, Little et al. 2009, Haupt,
Deichsel et al. 2014, Hildebrand, Stange et al. 2017, Haupt, Xu et al. 2018).
Since ligand binding has been shown to be important for complex assembly
(Attisano, Wrana et al. 1996, Allendorph, Vale et al. 2006, Allendorph, Isaacs et
al. 2007, Little and Mullins 2009), these results imply that this signaling activity
also occurs independent of complex assembly. However, our results still show
that presumptive GS domain phosphorylation by the type II BMP receptors is still
required by ACVR1-R206H and -G328R (Le and Wharton 2012, Bagarova,
Vonner et al. 2013, Hino, Ikeya et al. 2015). In the absence of complex
assembly, GS domain phosphorylation could occur via several methods:
stochastic association of FOP-ACVR1, transphosphorylation by receptors in
other TGF-beta signaling complexes, and autophosphorylation. Though these
possibilities have been speculated (Weis-Garcia and Massague 1996, Bagarova,
Vonner et al. 2013), none have been definitively shown to occur. The ability of
ACVR1-R206H to signal with only the extracellular domains of type II BMP
receptors, implies that phosphorylation can occur by one type I BMP receptor to
another or by autophosphorylation. The stricter GS domain serine/threonine
residue requirements of ligand-independent signaling by ACVR1-R206H implies
that in the absence of a receptor complex, certain serine/threonine residues are
not accessible for phosphorylation. Alternatively, if the type I receptors are the
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source of kinase activity, they may only be able to phosphorylate certain residues
within the GS domain.
Our data and others shows that FOP-ACVR1 has the ability to respond to
BMP ligand. Studies have also found that FOP-ACVR1 has acquired the ability to
signal in response to the TGFb superfamily ligand, Activin A (Hatsell, Idone et al.
2015, Hino, Ikeya et al. 2015, Lees-Shepard, Nicholas et al. 2018). The ability of
FOP-ACVR1 to signal with a greater repertoire of ligands, implies that it can also
signal with a greater repertoire of receptors, especially considering ligand
diversity and their role in specifying the components of signaling complexes. The
reduced GS domain activation requirement by ACVR1-R206H mutation in
particular may allow ACVR1 to signal in novel complexes. These complexes in
particular may reflect complexes that occur in vivo but do not normally have the
capacity to signal.
5.3: Activin and zebrafish as a model of HO
Due to the ability of Activin A to activate Nodal pathway signaling, we were
unable to evaluate the ability of this ligand to stimulate FOP-ACVR1 in our
system. Activin A overexpression in a one-cell stage embryo leads to expansion
of the dorsal shield structure and to arrest in epiboly leading to embryonic death
before DV patterning phenotypes can be assessed. While restricted
misexpression of Activin A in early gastrula embryos is conducive with life and
can rescue loss of Nodal signaling (Gritsman, Zhang et al. 1999), it is unlikely
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that restricted misexpression of Activin A would be sufficient to observe changes
in DV patterning with FOP-ACVR1 without interfering with epiboly.
Interestingly, Activin A does not induce HO in a zebrafish model of FOP
(LaBonty, Pray et al. 2017, LaBonty, Pray et al. 2018). This may be due to
insufficient heat shock induction of ACVR1-Q207D. Alternatively the regenerative
capabilities of the zebrafish may prevent HO formation. Activin is important for
regeneration of heart and tail and is highly expressed during these processes
(Jazwinska, Badakov et al. 2007, Dogra, Ahuja et al. 2017). Another regenerative
animal, the spiny mouse, has been shown to produce reactive oxygen species in
response to injury to break up fibrotic tissue (Simkin, Gawriluk et al. 2017). The
establishment of fibrotic tissue is an important primary step in the formation of
HO, so an animal that can prevent the formation of fibrotic tissue may be
resistant to HO.
Activin A has been shown to activate pSmad1/5 signaling in multiple
myeloma cells and Activin B can do so in liver cells, suggesting that its receptor
affinity and signaling activity may be different in different tissues (Canali, Core et
al. 2016, Olsen, Sankar et al. 2018). Though Nodal was not identified as a ligand
that signals through FOP-ACVR1, its affinity for the same receptors as Activin A
implicate it as a possible ligand in signaling by FOP-ACVR1 (Gritsman, Zhang et
al. 1999).
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5.3 Differences between FOP-ACVR1 mutants
Our study highlights several differences in the activity of ACVR1-R206H
compared to ACVR1-G328R, that are mutant for residues in the GS domain and
kinase domain, respectively. Both have ligand-independent and ligandresponsive activity, though G328R appears to have a more dramatic response to
BMP ligand (Haupt, Xu et al. 2018). In addition, ligand-independent signaling by
ACVR1-G328R appears to have more GS domain phosphorylation requirements
than ACVR1-R206H.
While most FOP mutations occur in or around the GS domain on the 3-D
structure of ACVR1, there are differences in what parts of the GS domain they
interact with. Unfortunately, there is no complete crystal structure of the GS
domain of ACVR1. The most complete structure of the intracellular domain of
ACVR1 contains most of the GS domain (Williams, Pinkas et al. 2019).
Importantly this crystal structure is missing the amino acids 187-191 (SCTSG)
which includes the residues T189 and S190. Interestingly, residue G328 (the site
of the G328R mutation) appears to associate very closely to residues S192 and
S194 (Fig 5.2). Conversely the R206 residue (the site of the R206H mutation) is
separated from S192 and S194 by other amino acids but occurs close to where
T189 and S190 may theoretically lie. These differences in proximity may account
for some of the differences in how these FOP mutants signal in the absence of
certain GS domain serine/threonine residues.
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Figure 5. 2: The ACVR1 GS and Kinase domain crystal structure. The
R206H mutation occurs (red, right) within the GS domain and the G328E, R and
W mutations are (red, left) within the kinase domain. Two serine/threonine
residues within the GS motif have a predicted crystal structure, S192 (teal,
upper) and S194 (teal, lower). The area where T189 and S190 are expected to
reside has not been characterized (black circle) (Williams, Pinkas et al. 2019).

Proximity between serine/threonine residues and FOP mutations may play
a role in the signaling activity of different mutants. Interestingly, most FOP
mutants (L196, P197, R202, G207, and R258) occur around the area where
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T189 and S190 is expected to reside (Fig 5.3). The L196 and R258 mutants fall
in close proximity to all four serine/threonine residues, suggesting they may have
the ability to compensate for loss of serines and threonines more readily.
Interestingly two of the kinase domain mutations, at G356 and R375, do not fall
in close proximity to any of the serine/threonine residues within the GS motif.
These mutations may interact with the GS domain in unexpected ways, or they
may alter ACVR1 signaling function in completely different ways from other FOP
mutants, such as by changing the shape of the kinase domain.

Figure 5.3: The ACVR1 GS and Kinase domain crystal structure. All FOP
mutations occur in the intracellular domain of ACVR1. The FOP mutants
investigated in this study occur at R206 and G328 (red). Other FOP mutations
have been identified at L196, P197, R202, Q207, R258, G356 and R375
(maroon). Most of these mutations occur in close proximity to the
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serine/threonine residues within the GS motif, S192 and S194 (teal). Structure
shown from 3 lateral views and one top down view (Williams, Pinkas et al. 2019).

As discussed earlier, clinically this ligand-independent signaling activity
may represent a higher baseline signaling activity that leads to spontaneous
heterotopic ossification (HO) in FOP patients (Shore and Kaplan 2010). The
difference in GS domain serine/threonine residue requirements between ACVR1R206H and ACVR1-G328R may represent a difference in baseline signaling
activity. In addition, ligand responsive signaling activity may parallel injury
induced HO. During an inflammatory event TGFb ligands, Activin A in particular,
are in abundance to activate signaling complexes. Increased abundance of other
TGFb receptors may also occur during inflammation, providing more possible
signaling complexes for FOP-ACVR1 to participate in.
It would be interesting to re-evaluate the phenotype of these two
mutations in light of these differences in signaling activity. The difference
between ACVR1-R206H and ACVR1-G328R may be reflected in the progression
of disease. One might speculate, if ACVR1-R206H has a higher baseline activity,
this may be reflected by an increased incidence of spontaneous HO compared to
ACVR1-G328R. ACVR1-G328R may in turn have a higher incidence of injuryinduced HO due to greater ligand responsiveness. Conversely ACVR1-R206H
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may have a higher incidence in injury-induced HO despite appearing to be less
responsive to ligand due to a lower overall activation threshold.
5.4: Future Directions
5.4.1: Type I Receptor partners
Since other TGFb receptors are within the developing zebrafish and
available for FOP-ACVR1 to associate with, it would be interesting to further
assess the role of these receptors in signaling by FOP-ACVR1. TGFbR1 has
been shown to signal with ACVR1 through pSmad1/5 (Ramachandran, Vizan et
al. 2018), though knocking down TGFbR1 individually in vitro had no effect on
singaling by ACVR1-R206H (Hino, Ikeya et al. 2015). Both Tgfbr1a and Tgfbr1b
are detectable at low levels in early development of the zebrafish by RNAseq
(White, Collins et al. 2017). Knocking down TGFbR1 in conjunction with the other
type I BMP receptors would reveal if TGFbR1 can compensate for loss of other
type I BMP receptors. Alternatively, the receptors FOP-ACVR1 complexes with
could be further assessed with co-immunoprecipitation. Since zebrafish receptor
antibodies are not available, this would require injection of epitope-tagged
receptors to detect association between them. Pull down of FOP-ACVR1 and
subsequent mass spectrometry evaluation could be used to identify other
receptor and ligand partners. In addition, mass spectrometry may identify other
non-ligand or receptor protein components within the ACVR1 and FOP-ACVR1
signaling complexes and how they differ.
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5.4.2: Type II receptor partners
While our results show that presumptive phosphorylation of the GS
domain is required for FOP-ACVR1 to signal, we did not identify which type II
BMP receptors are required for FOP-ACVR1. Based on data from our lab,
Acvr2b appears to be important for zebrafish DV patterning (Benjamin Tajer,
unpublished). By RNAseq, while Acvr2a and Acvr2b are expressed throughout
development, Bmpr2 is not expressed until late gastrulation (White, Collins et al.
2017). This would suggest that ACVR2a and b are sufficient to allow FOPACVR1 to over-activate BMP pathway signaling. Injecting FOP-ACVR1 mRNAs
into type II BMP receptor mutants or in wild-type fish with type II BMP receptor
morpholino knock down would help reveal which type II receptors are necessary
or sufficient for signaling by FOP-ACVR1.
5.4.3: ACVR1-R206H structure
Our results identified which GS domain residues in particular are important
not only to signaling by FOP-ACVR1, but also wild-type ACVR1. Predicting GS
domain structure in signaling and non-signaling ACVR1 may be more easily
elucidated knowing which residues presumably must be phosphorylated for
signaling to occur. We also found that the human kinase domain was sufficient to
impart over-active signaling to the normal not overactive zebrafish Acvr1l-R203H.
Identifying the differences between the human and zebrafish kinase domains that
allow this change in signaling may give unique insight into how FOP-ACVR1
imparts disease. Crystallization of our GS domain mutants and our zebrafish126

human ACVR1 chimeras may give further information about conformations that
prevent signaling, allow normal signaling or allow over-active signaling.
5.4.4: Sufficiency of GS domain residues for signaling
Finally, we have shown that there are certain GS domain serine/threonine
residues that are important for signaling by FOP-ACVR1. Interestingly, no FOP
mutants have been identified at any of the serines or threonines themselves. This
may be due to chance, or it may be that phosphomimetic mutations to those sites
are not compatible with life. It would be interesting to generate phosphomimetic
mutation at the residues identified to be important for signaling by FOP-ACVR1
to determine if these residues must actually be phosphorylated for signaling or if
the changes we made simply resulted in changes to protein folding. Generating
phosphomimetic mutants may allow us to identify which residues are sufficient to
allow signaling when phosphorylated.
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Glossary
ACVR1 – Activin A Receptor type I
ACVR2 – Activin A Receptor type II
BMP – Bone Morphogenetic Protein
BMPR1 – Bone Morphogenetic Protien Receptor type I
BMPR2 – Bone Morphogenetic Protien Receptor type II
DV - Dorsoventral
FOP – Fibrodysplasia ossificans progressiva
GS domain – Glycine/Serine domain
HO – Heterotopic Ossification
TGFb - Transforming Growth Factor Beta
Type I BMP receptors – transmembrane TGFb/BMP family kinase receptors that bind BMP and
phosphorylate Smad1/5 (ACVR1 and BMPR1)
Type II BMP receptors – transmembrane TGFb/BMP family kinase receptors that bind BMP and
phosphorylate Type I BMP receptors (ACVR2 and BMPR2)
Smad1/5 – Mothers Against Decapentaplegic Homolog 1 and 5
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